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Abstract 
 
DNA methylation is a gene silencing mechanism. In cancer the normal 
pattern of DNA methylation is often disrupted; silencing tumour suppressor 
genes and leading to uncontrolled progression through the cell cycle. 
Therefore DNA demethylating agents represent a promising therapeutic 
pathway to pursue. While 5-Aza-2’deoxycytidine (DAC) is a demethylating 
agent approved by the FDA for the treatment of myelodysplastic syndromes 
(MDS) and its use thus far has been confined to haematological 
malignancies, current research suggests treatment may be transferable to 
solid tumours. Progress in this area has been hindered by toxicity at higher 
doses however low doses of DAC may provide the benefits of DNA 
demethylation without the toxic side effects. In this project I examined the 
effect of various concentrations of DAC on two oral cancer cell lines; Vu40T 
and Scc040. Data indicated that a concentration as low as 100nM DAC was 
sufficient to reactivate the tumour suppressor gene RARβ in Vu40T cells. 
However this result is specific as it differed between the cell lines and 
culture method used. Furthermore DAC treatment lead to an increase in      
5-hydroxymethycytosine (5hmC) levels in both cell lines and a 
corresponding increase in TET2 gene expression suggesting that DAC 
reactivates TET2 which then converts 5mC to 5hmC. These results suggest 
that the benefits of low dose DAC may be transferable to the treatment of 
solid tumours and provides two potential mechanisms by which it exhorts 
its effects in oral cancer. 
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Introduction  
 
Oral Cancer 
Oral cancer is becoming a major health problem with the World Health 
Organization predicting an increase in cases for decades to come (Sciubba, 
2001). The term covers cancers of the oral cavity, oropharynx and lip vermilion 
with the vast majority of cases being oral squamous cell carcinomas (OSCC) 
which arise from the oral mucosal lining (Neville and Day, 2002). As with all 
cancers OSCC is a multifactorial disease and excessive tobacco or alcohol 
consumption and HPV infection contribute to increased risk (Gasche and Goel, 
2012). What is of increasing interest in oral cancer research is the dysregulation of 
gene expression via epigenetic modifications (Gasche and Goel, 2012).  
 
DNA Methylation 
This project studies one aspect of epigenetics specifically: DNA methylation. DNA 
methylation is the addition of a methyl group to a DNA base, usually position five 
of the pyrimidine ring of cytosine in CpG dinucleotides, a reaction catalysed by the 
DNA methyl transferases (DNMTs) (Gasche and Goel, 2012). The modification is 
associated with gene silencing via Methyl-CpG-binding proteins (MBPs) which 
liaise with co-repressors to bring about a closed chromatin state (Klose and Bird, 
2006). CpG sequences are underrepresented in the genome and the majority are 
methylated. The exception is CpG islands which are regions rich in CpGs usually 
found near gene promoters (Tsai and Baylin, 2011). 85-90% of these sites are left 
unmethylated in any given cell allowing the associated genes to be 
transcriptionally expressed (Tsai and Baylin, 2011). However in many cancers this 
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normal pattern of methylation is disrupted and the abnormal methylation of tumour 
suppressor genes can lead to uncontrolled progression through the cell cycle 
suggesting that demethylating agents may provide a promising therapeutic 
pathway to pursue (Tsai and Baylin, 2011). 
 
In a methylation array of 44 OSCC patient samples Jithesh et al. (2013) found that 
OSCC has a methylation profile distinct from that of healthy tissue with the 
majority of probes examined being hypermethylated in the OSCC samples. A 
similar result was found by Jäwert et al. (2013) who used immunohistochemical 
analysis to compare oral mucosal samples from healthy patients to those with 
OSCC and found the methylation levels in OSCCs were significantly higher. 
Additionally multiple genes known to be associated with tumour suppression are 
found to be hypermethylated in oral cancers including APC, p14ARF, E-Cadherin 
and RARβ with this silencing contributing to tumour progression (Gasche and 
Goel, 2012).  
 
DNA Hydroxymethylation  
DNA methylation is reversible and this is known to be an active process in certain 
situations however exactly how it is regulated is unclear.  The discovery that 5-
methylcytosine (5mC) can be oxidised to form 5-hydroxymethylcytosine (5hmC) 
which can then be converted to 5-formylcytosine (5fC) and finally to 5-
carboxylcytosine (5caC) has provided a potential mechanism for DNA 
demethylation as 5caC can be converted back to cytosine in either an active or a 
passive process (Tahiliani et al., 2009; Ito et al., 2011; He et al., 2011; Piccolo and 
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Fisher, 2014). This reaction is catalysed by the TET protein family (1, 2, 3) of Fe2+ 
and α- ketoglutarate (α-KG) dependent dioxygenases (Ito et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
In addition to analysing the methylation status of oral mucosal samples Jäwert et 
al. (2013) determined the levels of hydroxymethylation and the TET2 protein. 
They identified a decrease in 5hmC in the cancerous samples compared with 
healthy oral epithelium. This corresponded with a decrease in TET2 providing a 
mechanism to account for this loss (Jäwert et al, 2013). Similarly Yang et al. 
(2013) demonstrated using dot blot and immunohistochemical analysis that the 
5hmC levels in various other organs were much lower in cancerous tissue 
compared with healthy tissue in both mice and humans. They also demonstrated 
via quantitative PCR (qPCR) that the expression of all three TET genes was lower 
in cancerous tissue compared with the corresponding healthy tissue for breast 
carcinoma and hepatocellular carcinoma thus providing a potential mechanism to 
explain the loss of 5hmC (Yang et al., 2013). These results are in agreement with 
C. 
 
A. B. 
TETs 
D. 
C. 
E. 
Figure 1: DNA 
Demethylation 
Pathway. A: DNMTs 
catalyse the addition of 
a methyl group to 
position 5 of the 
pyrimidine ring of 
cytosine. B: TETs 
hydroxylate 5mC into 
5hmC. C-D: 5hmC can 
be further oxidised into 
5fC and 5caC if ATP is 
supplied. E: 5caC can 
be removed by thymine 
DNA glycosylase (TDG) 
and replaced with C or 
lost during DNA 
replication when the 
modification is not 
passed on to the 
daughter stand of DNA. 
Image adapted from 
Tan and Shi, (2012). 
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the theory that 5hmC is a step in the demethylation pathway and also suggests 
that 5hmC and the TET genes may have tumour suppressive functions. 
 
5-Aza-2’-Deoxycytidine 
Azacytidine (AZA) and 5-Aza-2’-deoxycytidine (DAC) are two demethylating 
agents that have proved effective in the treatment of haematological malignancies 
and as such are FDA (The US Food and Drug Administration) approved (Tsai et 
al., 2012). Both drugs are analogues of cytosine and are incorporated into DNA at 
cytosine sites. The use of these drugs has been limited by the fact that high doses 
are extremely cytotoxic however at low doses the positive effects of DNA 
demethylation may outweigh the negatives of DNA damage (Tsai et al. 2012). 
        
DNMT1 only methylates hemimethylated DNA; it copies DNA methylation onto the 
daughter strand after DNA replication making methylation heritable across cellular 
generations (Ghoshal et al., 2005). Both DNMT3a and DNMT3b are de novo 
methyl transferases (Gasche and Goel, 2012). Ghoshal et al (2005) found that the 
expression profile in DNMT1 knockout cells was similar to that of cells which had 
been treated with DAC. However, DNMT3b knockouts did not show the same 
pattern suggesting that DAC exerts its effects mainly through DNMT1.  When 
DAC is incorporated into DNA in place of cytosine, DNMT1 recognizes and binds 
covalently to the base (Stresemann and Lyko, 2008). When DNMT1 is bound to 
Figure 2: 5-Azacytidine 
(AZA) and 5-Aza-2’-
deoxycytidine (DAC) are 
cytosine analogues. Figure 
adapted from Leone et al. 
(2003). 
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cytosine this bond is rapidly removed however the binding of DAC is more stable 
and hence it becomes trapped on DNA (Stresemann and Lyko, 2008). This is 
thought to lead to the cytotoxic effects of DAC as it can cause DNA damage and 
notably when DNMT1 is reduced the toxicity of DAC is also reduced (Jüttermann 
et al., 1994). DNMT1 is then selectively degraded by the proteasomal pathway 
hence DAC treatment leads to a decrease in available DNMT1 and a 
corresponding decrease in methylation (Ghoshal et al., 2005). As such the levels 
of DNMT1 in the cells contribute to the efficacy of the drug and may explain why 
some cancers are resistant to treatment. 
 
5-Aza-2’-deoxycytidine was recently shown to have therapeutic benefits against 
myelodysplastic syndrome (MDS) in a randomized phase III clinical trials which 
lead to its approval by the FDA (Kantarjian et al., 2006). Further success has been 
found in its use in the treatment of other haematological malignancies such as 
acute and chronic myeloid leukemia (AML and CML) (Leone et al., 2003; Issa et 
al., 2004). High doses of DAC are subject to toxicities due to the generation of 
DNA adducts caused by the capture of DNMT1 however it has been observed that 
low doses are just as effective (Issa et al., 2004). Tsai et al. (2012) showed that 
low dose DAC caused a decrease in promoter methylation, subsequent gene re-
expression and the inhibition of subpopulations of cancerous cells not only in 
leukemic cells in vitro but also breast cancer cells demonstating that the benefits 
of low dose DAC may be transferable to solid tumours.  
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Retinoic Acid Receptors 
Retinoic acid receptors (RARs) are nuclear receptors for retinoids and their 
derivatives (Connolly et al., 2013). Activation of the receptors can induce 
differentiation in various cell types and as such their inactivation has been noted in 
various malignancies (Connolly et al., 2013). There are three types of RAR (α, β, 
γ) which form heterodimers with RXRs (α, β, γ) and bind to RA response elements 
(RAREs) which are DNA sequences located 5’ of RA induced genes (Connolly et 
al., 2013). In the absence of a ligand these associate with large protein complexes 
that bring about a condensed chromatin state (Duong and Rochette-Egly, 2011). 
However ligand binding induces a conformational change in the protein resulting 
in dissociation from co-repressors and the recruitment of co-activators leading to 
an open chromatin structure and transcription of associated genes (Duong and 
Rochette-Egly, 2011).  
 
The expression of RARβ is dependent upon activation of RARα as RARβ is one of 
its downstream targets. However once active RARβ can regulate its own 
expression along with that of its target genes (Connolly et al., 2013). The genes 
regulated by RARβ are generally associated with cell differentiation and death 
hence RARβ is associated with tumour suppression and is commonly mutated or 
epigenetically silenced in solid tumours (Connolly et al., 2013). Low levels of 
RARβ expression are seen in premalignant oropharyngeal lesions indicating that 
gene activity is often lost early in tumourgenesis (Lotan et al., 1995). In most 
cases this loss of expression can be restored by treatment with retinoic acids 
however this is not always the case (Lotan et al., 1995). Epigenetic silencing of 
RARβ is thought to contribute to the lack of success of RAs in cancer treatment as 
9 
 
pharmacological doses of RA are not always sufficient to reactivate the gene, the 
repressive marks must also be removed. By using a combination of all-trans 
retinoic acid (ATRA), DNA methyltransferase inhibitors and histone deacetylase 
inhibitors Raffoux et al. (2010) had some success in the treatment of AML and 
MDS. 
 
3D Cell Culture 
Traditionally cancer cell lines have been grown in monolayers on culture-
plasticware as this has provided a relatively easy to use system where various 
aspects of cell biology can be examined. However this is not an accurate model of 
how tumour cells behave in vivo and subsequently 3D systems have been 
developed to provide better in vitro representation (McCaffrey and Macara, 2011). 
These models allow for studies into morphogenesis and tumour invasion however 
they also show distinct differences in gene expression compared with 2D culture 
with the expression profiles of 3D cultured cells being more reminiscent of in vivo 
tumours compared with the same cells grown in monolayers (Ridky et al., 2010). 
 
Aims and Objectives 
This project aims to determine the effect of varying concentrations of 5’-Aza-2-
deoxycytidine (DAC) on oral cancer cell lines either alone or in combination with 
9-cis retinoic acid (RA). As relatively high doses have been shown to have harmful 
side effects the concentrations of DAC used in this project will range from 1μM to 
10nM in order to determine the lowest concentration of DAC required to 
demethylated DNA. The efficacy of the treatment model will be assessed by 
determining changes in: 
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 -RARβ gene expression; 
 -Local and global cytosine methylation levels; 
 -Global 5’ hydroxycytosine levels. 
 
Two different oral cancer cell lines will be used to potentially replicate the diversity 
of in vivo tumours. Scc040 and Vu40T are both HPV-negative human oral cancer 
cell lines and despite their similarities, variation in the efficacy of the drugs on the 
two cell lines is likely. 
 
Gene expression of a single cell line varies with the method of culture used; from 
2D to 3D and even between the different methods of 3D culture (Ridky et al., 
2010; Khan et al., 2012). Therefore an additional aim of this project is to 
determine whether growing and treating cells in 3D culture instead of traditional 
2D monolayer has any effect on susceptibility to DAC. The 3D culture method 
used here involved seeding the cells onto a collagen raft embedded with 
fibroblasts. This construct is subsequently grown on the surface of the culture 
medium so that the liquid air interface is maintained. This approach gives the cells 
orientation and hence they differentiate into the different epithelial layers.  
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Materials and Methods  
 
Cell Lines 
Two HPV negative human oral cancer cell lines were used in this study; Scc040 
(DSMZ) and Vu40T (a gift from Prof Hans Joenje, Free University of Amsterdam). 
Cultures were maintained in Dulbecco’s Modified Eagles Medium (Sigma- Aldrich) 
supplemented with 10% fetal bovine serum, 5mg/ml penicillin-streptomycin 
(Gibco), 2mM L-glutamine, 0.1mM non-essential amino acids (Gibco) and 1mM 
sodium pyruvate (Gibco) in 37oC and 5% CO2. 
 
Drug Treatments 
For both cell lines 5x104 cells were seeded onto a well of a 6 well plate for each 
treatment. This was performed in duplicate allowing one well for DNA extraction 
and one for RNA extraction. The drug treatments were performed over a 5 day 
period with the cells plated on day 1 and harvested on day 5 with the medium 
changed daily. 5-Aza-2’-deoxycytidine (DAC) was added to the medium on day 1 
and 9-cis Retinoic Acid (RA) (Sigma-Aldrich Catalogue no: R4643) added on day 
3 so that the cells were treated with 96 hours DAC and 48 hours RA. The cells 
were grown in 37oC, 5% CO2 in the dark as RA is sensitive to light.  
 
For each cell line the following combinations of drugs were used:  untreated 
control, 10nM DAC, 100nM DAC, 500nM DAC, 1µM DAC, 1µM RA, 10nM DAC + 
1µM RA, 100nM DAC + 1µM RA, 500nM DAC + 1µM RA, 1µM DAC + 1µM RA. 
Two independent experiments were performed for Vu40T cells and three 
independent experiments for Scc040 cells.  
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DNA Extraction 
Cultures were harvested for DNA extraction by washing in PBS solution (Sigma- 
Aldrich) twice, adding 750μl 0.25% trypsin (Gibco), allowing to trypsinize and 
inactivating with an equal volume of medium. The cells were then centrifuged for 5 
minutes at 13000rpm to form a pellet, washed in cold PBS and stored at -20oC. 
 
DNA extraction was performed using the DNeasy Blood and Tissue kit (Qiagen) 
as of the blood and cell culture protocol. Briefly cells are first lysed with proteinase 
K and buffer AL then the DNA precipitated using 100% ethanol. The solution was 
then transferred to a spin column and centrifuged with a series of wash buffers to 
clean the DNA and remove ethanol from the sample. Once washed and dried the 
DNA was eluted in 200µl AE buffer and concentration determined using a 
NanoDrop. 
 
Slot Blots 
For each sample 1µg (or 500ng) of DNA was combined with 120µl 1M NaOH and 
6µl 500nM EDTA up to a final volume of 300µl with dH2O and a final concentration 
of 0.4M of NaOH. These were prepared in duplicate and heated at 100oC for 10 
minute to denature the DNA. The manifold was assembled with a sheet of filter 
paper under a sheet of nitrocellulose membrane both soaked in dH2O for 10 
minutes prior to assembly. The slot blot manifold was attached to a low level of 
suction and the wells washed with dH2O. The heated samples were then added to 
the wells and allowed to pass through the slots onto the membrane. After all 
samples had passed through the slots 500µl 0.4M NaOH was added. The 
membrane was washed briefly in 2X SCC, allowed to dry and blocked for 1 hour 
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in 5% non-fat milk in dH2O. The primary antibodies used were 5mC (Active Motif, 
Catalogue no. 39649) at a dilution of 1:1000 and 5hmC (Active Motif, catalogue 
no. 39769) at a dilution of 1:5000 both in 5% milk.  
 
The primary antibodies were washed off in 5% milk, the secondary antibody 
added to the membranes (anti-mouse 1:5000 in 5% milk) and allowed to bind for 2 
hours in 4oC. This was then washed in PBS. The membranes were then treated 
with Amersham ECL western blotting detection reagents (GE Healthcare, 
catalogue no.RPN2106) for 1 minute before the slots were visualised. 
 
ImageJ was used to determine the intensity of each band on the slot blots 
(Schneider et al., 2012). The results of each repeat were combined and density is 
shown relative to the band for the untreated control cells. 
 
RNA Extraction, cDNA Synthesis and qPCR 
RNA extraction was performed using the Qiagen RNeasy Mini kit as the protocol 
recommends. Briefly cultures were harvested by washing the wells twice in PBS 
solution (Sigma-Aldrich) then adding 500µl RLT buffer (Qiagen RNeasy kit) + 5µl 
β-mercaptoethanol.  Following 5 minutes digestion the solution was homogenized 
using a 1mm needle and syringe and stored at -80oC prior to use. Once defrosted 
70% ethanol was added to homogenates; the solution transferred to an RNeasy 
spin column and the liquid removed by centrifugation for 15 seconds at 13000rpm. 
The spin column membrane was then washed in RW1 buffer and DNase added to 
digest any DNA contaminants. RPE buffer was added to the membrane and the 
spin column centrifuged at 13000rpm twice followed by a single 13000rpm 
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centrifugation in a clean collection tube to dry the membrane. Final RNA was 
eluted into 40µl nuclease free H2O and a NanoDrop used to determine the 
concentration. 
 
cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad) from 1µg 
RNA and 0.1μl of reverse transcriptase. Using a thermal cycler the reaction mix 
was incubated at 25oC for 5 minutes, 42oC for 30 minutes then 85oC for five 
minutes.  
 
The Roche LightCycler 480 II qPCR system was used with 1µl cDNA, 0.075µl 
forward and 0.075µl reverse primers (all at 100mM), 6µl LightCycler 480 SYBR 
green master mix (Roche) and up to 12µl with dH2O. The absolute quantification 
method was used with a standard curve generated from cDNA standards of 
known concentration. Each analysis was performed in duplicate. 
 
qPCR Primers:  
 Forward (5’-3’) Reverse (3’-5’) 
RARβ TGCCAATACTGTCGACTCCA CTCTGTGCATTCTTGCTTCG 
RARα GACCAGATCACCCTCCTCAA CATCTGGGTCCGGTTCAG 
GAPDH CCTGGCCAAGGTCATCCAT AGGGGCCATCCACAGTCTT 
TET1 TCATGGGTGTCCAATTGCTA GATGAGCACCACCATCACAG 
TET2 GGACATGATCCAGGAAGAGC CCCTCAACATGGTTGGTTCT 
CK5 CCAAGCCAATTGCAGAACCA AAATTTGGGATTGGGGTGGG 
CK6 GTCCTCAGGCCCCTCTCTGG CCCCTGGCAATTTTCTGCAA 
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qPCR Data Analysis 
For each sample the concentration of RNA was determined from the number of 
cycles taken for it to cross the threshold fluorescent level (Crossing point, or Cp 
value). The concentration of the gene of interest for each sample was then 
normalised to the corresponding control gene (GAPDH or RARα). For each 
treated sample a fold change was generated against the untreated control cells. 
Each cDNA sample was analysed twice and a mean fold change was generated 
from all the biological and technical replicates for each sample and this is what is 
displayed in the figures. Microsoft excel was used to calculate standard deviations 
from the mean and these are shown as error bars. Excel was also used to perform 
the t-test on each sample against the untreated control cells to determine any 
significance in the findings: * = p-value<0.05, **= p-value<0.01, ***=p-
value<0.005. 
 
Bisulfite Conversion and Restriction Digest 
Bisulfite conversion was performed using the Qiagen EpiTect Bisulfite conversion 
kit as the protocol recommends. In brief 500ng DNA was mixed with DNA protect 
buffer and bisulfite mix and conversion carried out in a thermal cycler (Program: 
95oC 5min, 60oC 25min, 95oC 5min, 60oC 85min, 95oC 5min, 60oC 175min). Once 
complete the converted DNA was transferred to an EpiTect spin column and a 
series of buffers and centrifugation steps were used to clean the bisulfite 
converted DNA.  
 
Primers were designed for RARβ transcription start site using the MethPrimer 
programme to generate primers specific to bisulfite converted DNA (RARβ Fwd: 
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AGAGGTAGGAGGGTTTATTTTTTGT, RARβ Rev: 
CAAATTCTCCTTCCAAATAAATACTTA) to generate a 182 base pair fragment. 
These were used to amplify the converted DNA using 2X Taq polymerase master 
mix (Thermo Scientific). Taqα1 restriction digest was then performed on 10μl of 
the PCR product using NEBuffer 4 (New England Biolabs), BSA (New England 
Biolabs) and 4 units of Taqα1 enzyme (New England Biolabs). These were 
incubated at 65oC for one hour and inactivated at 85oC for 20 minutes. The end 
products were electrophoresed on a 2% agarose gel in 0.75X TBE. 
 
Raft Culture 
3D organotypic raft culture was performed as previously described (Wilson et al., 
2005) in collaboration with Dr Sally Roberts (School of Cancer Sciences, 
University of Birmingham). In brief Vu40T cells were seeded onto collagen rafts 
embedded with fibroblasts. The cells were cultured in Emedium (a gift from Dr 
Sally Roberts) supplemented with 10ng/ml epidermal growth factor (EGF) until 
fully confluent and then raised onto a metal grid. The grid was placed in a petri 
dish of Emedium without EGF with the medium touching the bottom of the grid 
and the top of the cells exposed to the air. Medium was changed every 48 hours 
and the cells cultured for 11 days with 100nM DAC added to the medium of one 
raft 4 days prior to harvest. The collagen was removed from the cells using a 
scalpel and each raft dissected into four equal sections, for RNA and DNA 
extraction purposes as described above. 
  
17 
 
Results 
 
Sensitivity to DAC Varies Between Cell Lines. 
In this study two oral cancer cell lines were studied, Scc040 and Vu40T. The cells 
were treated to four days of 5-Aza-2’-deoxycytidine (DAC) at varying 
concentrations with or without 9-cis retinoic acid (RA) for the final two days of 
culture. The effect of lower concentrations of DAC was of particular interest and 
the concentrations used were 10nM, 100nM, 500nM and 1µM DAC. Notably Tsai 
et al. (2012) classified very low doses as being in the range of 20-300nM for DAC 
treatment. Data indicated that 10nM of DAC had minimal effect on growth, gene 
expression, methylation or hydroxymethylation levels in either cell line. Figure 3A 
shows how the two cell lines responded differently to treatment. Vu40T cells were 
more susceptible to DAC with the density of cells after four days of 1µM DAC 
being considerably lower than the controls. Scc040 cells were also affected by 
treatment however this response was less evident (Figure 3A). The addition of RA 
to the treatments did not appear to have a significant effect (Figure 3B) and 
images allow for observations into differences between the two cell lines 
susceptibility to the drugs. MTT assays previously undertaken by the laboratory 
(unpublished/ personal communications) support these observations with IC50 
established for both cell lines in response to DAC with Vu40T at 0.5-2.15μM and 
Scc040 above 9μM. 
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Figure 3: Efficacy of 
Treatment Varies With The 
Cell Line Used. 5x10
4
 cells 
were seeded onto a well of a 
six well plate and cultured in 
treated or untreated media. 
Images were captured at 20X 
magnification and the colour 
inverted for clarity. A: Images 
of Vu40T and Scc040 cells 
were captured every 24 hours 
after seeding to show 
differences in the growth 
patterns in response to DAC 
treatment .a.=untreated 
control, b.=10nM DAC, c.= 
100nM DAC, d.=500nM DAC, 
e.=1µM DAC. B: The addition 
of 1µM RA had minimal effect 
on the growth of Vu40T and 
Scc040 cells after 72hours of 
DAC treatment and RA added 
in the final 24hours. 
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In Vu40T Cells DAC Treatment Causes a Reduction in Levels of 5mC and 
Increased Expression of RARβ 
To determine the efficacy of DAC treatment slot blot analysis was applied 
determine the methylation status of DNA under different concentrations of DAC 
(Figure 4A). This entailed blotting 1000 or 500ng of DNA onto a nitrocellulose 
membrane and using an antibody to detect the presence 5mC. The results 
showed a gradual decrease in 5mC in keeping with the increase of DAC treatment 
confirming that DAC causes a reduction in global 5mC levels (Figure 4A). The 
addition of 9-cis retinoic acid appeared to slightly increase this reduction in 5mC 
though the mechanism(s) which account for this are unclear (Figure 4A). This may 
be an artefact of the slot blot technique which can be variable or it could be due to 
increased activation of the retinoic acid receptors and therefore increased 
expression of their various target genes, one of which may have an effect on the 
methylation status of the cells. The entire experiment was repeated twice and 
each sample was loaded into two separate wells of the slot blot manifold. ImageJ 
was used to quantify the intensity of each slot and combine all four results (Figure 
4B). This is shown relative to the untreated control cells (Figure 4B). 
 
This project aimed to determine the minimal dosage required to cause a decrease 
in methylation and reactivation of the tumour suppressor gene, RARβ. 
Quantitative PCR (qPCR) was used as quantifiable means of determining how 
gene expression changed in response to DAC treatment. For the Vu40T cells a 
dose-dependent increase in RARβ RNA was observed in response to DAC 
treatment suggesting that the RARβ promoter is methylated in untreated cells 
(Figure 4C). Two different genes were used as a control in this experiment: RARα 
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and GAPDH. GAPDH was used as it is known to be constitutively expressed and 
RARα was used for two reasons; one it is reported to be expressed constitutively 
and secondly RARβ activation is dependent upon its expression (Campos et al., 
2009; de The et al., 1990). The 10nM concentration of DAC did not cause an 
increase in gene expression suggesting that the dose was too low to induce this. 
However 100nM DAC resulted in an almost a five-fold increase in RARβ RNA 
compared with the untreated cells when normalised to GAPDH and over double 
when normalised to RARα (Figure 4C). 1µM DAC resulted in 15X higher RARβ 
expression than untreated cells.  The addition of 1µM RA increased RARβ 
expression with RA only cells having the same increase as was detected for 
100nM DAC only treatment. Again 10nM exerted no effect but 100nM caused an 
increase in expression of almost 12 fold when combined with RA and 1µM DAC 
plus RA caused a 35 fold increase in gene expression (Figure 4C).  
 
To examine the local effect of DAC on RARβ promoter methylation bisulfite 
conversion and restriction digest were performed. The bisulfite treatment converts 
unmethylated cytosines to uracil but leaves 5mC and 5hmC unaffected. After 
bisulfite conversion a 182 base pair fragment of the RARβ transcription start site 
was amplified using PCR and this product was digested with the Taqα1 restriction 
enzyme. The enzyme dissects the nucleotide sequence TCGA so if this site was 
methylated the sequence would remain TCGA after treatment and therefore be 
dissected at two locations generating three fragments of 76, 17 and 86 base pairs. 
However unmethylated DNA will be converted into TTGA and so will not be 
recognized by the enzyme leaving a single fragment of 182bp. This is summarised 
in figure 4E. The results of this experiment showed that the site is methylated in 
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untreated Vu40T cells as previously hypothesized and this methylation is removed 
with DAC treatment from as little as 100nM. The band intensity for 100nM 
appeared similar to that of 1μM suggesting that low dose DAC causes local 
changes in DNA methylation (Figure 4D).  
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Scc040 Cells are Less Sensitive to DAC Treatment but May Respond to RA 
Alone. 
The experiment was repeated in another HPV negative HNSCC cell line. Scc040 
cells showed a higher resistance to DAC treatment as shown in Figure 3A and 
from previous results in the lab.  However the slot blots analyses confirmed that 
the demethylating activity of 5-Aza-2’-deoxycytidine was effective in both cell lines 
(Figure 4A-B; 5A-B). 
 
The results of the qPCR analyses showed that treatment with DAC alone had 
minimal effect on RARβ gene expression with 1µM DAC generating lower RARβ 
expression than the untreated cells (Figure 5C). However the addition of 1µM RA 
resulted in an increase in RARβ expression, with RA alone causing a three-fold 
increase which doubled when applied in combination with 1µM DAC (Figure 5C). 
When the initial levels of RARβ in the two cell types (Figure 5D) were compared 
Scc040 showed a higher basal expression than Vu40T. The bisulfite conversion 
 
Figure 4: 5’-Aza-2-deoxycytidine Treatment Causes a Decrease in Methylation and 
Subsequent Increase in RARβ Gene Expression in Vu40T Cells. 5x10
4
  Vu40T cells were 
seeded onto one well of a six well plate either in normal cell culture medium or medium with 
the addition of 5’-Aza-2-deoxycytidine(DAC) at varying concentrations for 4 days with or 
without 1μM 9-cis retinoic acid(RA) for the final 2 days of culture. Each experiment was 
performed in duplicate. A: Slot blots show 5mC decreased with DAC treatment. DNA was 
blotted onto a nitrocellulose membrane using the slot blot manifold.  This was exposed to a 
5mC primary antibody. Duplicate analyses were performed for each DNA sample. B: ImageJ 
data analysis determining slot blot intensity from A. Results are the mean of two independent 
experiments and are shown here relative to the untreated control cells. C: RARβ gene 
expression increases in a dose-dependent manner. qPCR results show expression 
normalized to RARα and GAPDH presented as a fold change. Results are means obtained 
from two independent experiments. Error bars represent standard deviation and significance 
is determined by t-test against the untreated control cells. *=p<0.05, **=p<0.01, ***=p<0.005. 
Unmarked bars are not significant. D-E: The RARβ promoter is methylated in Vu40T cells. 
DNA was bisulfite converted then a region surrounding the transcription start site amplified by 
PCR. The PCR product was dissected using Taqα1 at the sequence TCGA only in previously 
methylated samples. This product was then electrophorised on a 2% agarose gel. 
U=unmethylated, M=methylated. The band represents the 182bp uncut fragment. 
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and restriction digest results show that treated Scc040 cells are at least partially 
unmethylated at the RARβ site however untreated cells and those treated only 
with 1µM DAC show faint bands at the 182bp size suggesting that some of the 
DNA may be unmethylated (Figure 5E).   
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DAC Increases Expression of TET2 Leading to an Increase in 5hmC Levels.  
The effect of DAC and RA on levels of 5hmC was determined via slot blot 
analysis. 5hmC results from the oxidation of 5mC therefore 5mC must first be 
present in order to make 5hmC. Subsequently this lead to the initial hypothesis 
that treatment with DAC and therefore DNMT1 inhibition would lead to decreased 
levels of 5hmC as was seen for 5mC (Figures 4and 5A). However it was found 
that this was not the case, instead the global levels of 5hmC were increased in 
cells treated with higher concentrations of DAC (Figure 6A).  This effect appeared 
in both cell lines and was only apparent in the highest concentrations examined 
with 10nM and 100nM having minimal or no effect. The levels of 5hmC in cancer 
cells has been reported previously to be very low (Jäwert et al, 2013) and this was 
confirmed in the slot blot results for both cell lines (Figure 6A). Additionally 
treatment with RA either alone or in combination with DAC resulted in an increase 
in 5hmC levels in both cell lines (Figure 6A). 
 
 
Figure 5: 5’-Aza-2-deoxycytidine (DAC) Causes a Decrease in Global Methylation but 
RARβ Expression is Only Affected by 9-cis Retinoic Acid (RA) in Scc040 Cells. 5x104 
Scc040 cells were plated onto 6 well plates and treated with varying concentrations of DAC 
for 4 days with or without 1μM RA for the final 2 days of culture. A: Slot blots of treated and 
untreated Scc040 DNA blotted onto a membrane and incubated with 5mC antibody 
overnight. Each sample was run twice. B: ImageJ data for slot blots from A shown as density 
of the bands for each treatment relative to the control sample. Results are the mean 
obtained from two independent experiments. C: qPCR results show that RARβ gene 
expression is increased by RA but not DAC treatment. Results are normalized to GAPDH 
and RARα and shown as a fold change. Results are the mean obtained from two 
experiments. Error bars show standard deviation. Significance is all in comparison with the 
untreated cells *=p<0.05, **=p<0.01, ***=p<0.005. Unmarked bars are not significant. D: 
Mean RARβ RNA concentrations for Scc040 and Vu40T cells under RA and DAC treatment. 
Results are normalized to RARα. E: Bisulfite converted DNA at the RARβ transcription start 
site was digested with Taqα1 restriction enzyme. Methylated samples (M) retain restriction 
site whereas unmethylated samples (U) remain uncut. The product was separated on a 2% 
agarose gel. The 182bp band represents the uncut fragment. 
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In order to determine why this might be the case qPCR was performed on the 
same samples to identify corresponding changes in TET gene expression. The 
TET proteins are known to catalyse the conversion of 5mC to 5hmC so changes 
in TET gene expression in response to DAC treatment could account for the 
increase in 5hmC observed in the slot blots. Unfortunately the TET3 primers 
yielded no results so we were unable to determine the effect of DAC on TET3 
expression. In Vu40T cells increasing the concentration of DAC above 10nM 
resulted in a decrease in TET1 gene expression (Figure 6B) either on its own or in 
combination with RA. Treatment with 100nM, 500nM and 1µM of DAC caused a 
reduction in TET1 RNA of over 60% (Figure 6B). TET1 expression in Scc040 cells 
was unaffected by DAC treatment (Figure 6C). TET2 however showed an 
increase in gene expression which correlated with the increase in 5hmC levels 
seen in the slot blots analysis (Figure 6D-E). In both cell lines increasing the 
concentration of DAC caused an increase in the levels of TET2 RNA. For Vu40T 
cells the observed increase in TET2 expression after treatment with 500nM and 
1µM of DAC was 2.8 fold and 3.5 fold respectively (Figure 6D). TET2 expression 
in Scc040 cells was also dependent on DAC levels, both 100nM and 500nM DAC 
alone resulted in a doubling in TET2 mRNA, however 1µM DAC resulted in a fold 
change of almost 8 times (Figure 6E). The addition of RA increased these 
expressions however there was a large amount of variation between the replicates 
at the higher concentrations of DAC (Figure 6E). This result could be due to errors 
in the experimental procedure or may indicate that there is extreme variability in 
how sensitive Scc040 cells are to DAC and RA combined.  
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Figure 6: 5’-Aza-2-deoxycytidine (DAC) Increases Hydroxymethylcytosine Potentially 
Through Increased TET2 Gene Expression. Vu40T and Scc040 cells grown in the presence 
of DAC for 4 days either alone or in combination with RA for 2 days. Every experiment was 
performed in duplicate. A: Slot blots showing 5hmC increases with DAC treatment. DNA was 
blotted onto a nitrocellulose membrane and incubated over night with the 5hmC antibody. Each 
DNA sample was run twice. B-E: qPCR results are normalized to GAPDH and shown as a fold 
change. B: TET1 expression in Vu40T cells. C: TET1 expression in Scc040 cells. D: TET2 
expression in Vu40T cells. E: TET2 expression in Scc040 cells. 
A. 
E. D. 
C. B. 
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Vu40T Cells Grown in Organotypic Raft Culture Express Very Low Levels of 
RARβ Which Decrease upon Treatment with DAC.  
Growing cells in a monolayer is an efficient method however many aspects of 
these cells vary considerably from those in vivo. Therefore techniques which allow 
cells to grow and differentiate into 3D tissue have been developed and show gene 
expression profiles that resemble those of primary tissue more than their 2D 
counterparts (Ridky et al., 2010). This project aimed to further determine whether 
cultivating Vu40T cells in a 3D tissue environment had any effect on the levels of 
RARβ expression or on the effectiveness of DAC treatment. The 3D culture 
system used entailed growing the cells on a collagen raft including encapsulated 
fibroblasts above a wire mesh on the surface of the media so that the cells were 
fed from below and in contact with air from above (Figure 7A). This is known as 
the air liquid interface.  
 
The medium required for this system differed from the normal cell culture medium 
used in previous experiments. In order to make sure that Vu40T cells responded 
to DAC in the same way in this media (EMedia) the cells were either left untreated 
or treated with 100nM or 1µM of DAC in Emedia for four days and the expression 
of RARβ determined. Figure 7B shows the results of this experiment and it can be 
seen that DAC increases RARβ expression in EMedium in the same pattern as 
was previously observed (Figure 4C) but with even more dramatic fold changes 
detected.   
 
Khan et al. (2012) recently showed that epithelial cells grown on raft cultures 
expressed similar levels of cytokeratins (CK) 5 and 6 to corresponding primary 
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tissue. These were used as markers of differentiation to clarify that the raft culture 
enabled the cells to differentiate. qPCR was performed using CK5 and CK6 
primers on Vu40T cells grown in 2D and 3D culture. Both genes showed an 
increase in expression when grown in 3D culture in both treated and untreated 
cells with CK5 expression increased almost 25 times in the control cells indicating 
that the cells had differentiated (Figure 7C-D). 
 
Four days prior to harvesting the raft cultures one culture was treated with 100nM 
DAC. This was added directly to the medium and so the cells were exposed to the 
drug from below. The 5mC slot blot results showed that the drug was taken up by 
the cells through this route as the level of 5mC decreased in the treated sample 
(Figure 7E).  The 5hmC slot blot saw a corresponding increase, slightly higher 
than that observed in the 2D cultures (Figure 7E). The qPCR results showed that 
the 3D cultured cells expressed very little RARβ, none at all in the treated cells 
where GAPDH and RARα levels remained high (Figure 7F). RARβ expression in 
Vu40T cells appears always relatively low so this result could be due to 
inaccuracies in the qPCR and therefore further repeats are needed (Figure 7G).  
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Figure 7: Organotypic Raft Culture of Vu40T Cells. Vu40T cells were seeded onto a 
collagen raft embedded with fibroblasts. These were allowed to grow to confluence in the 
presence of Emedia. Once at confluence cultures were lifted onto a metal grid and grown at 
the air liquid interface for 11 days. 100nM of 5’-Aza-2-deoxycytidine (DAC) was added to the 
medium of one raft 4 days prior to harvest. Results shown are from a single experiment. A: 
diagrammatic representation of the raft culture system used. B: Vu40T cells were grown in 
Emedia (a specialised media for the 3D culture system) to determine whether the change in 
the media has any effect on the efficacy of DAC treatment. Results show the mean of two 
experiments, normalized to RARα or GAPDH and shown relative to the untreated cells. C-D: 
CK5 and 6 expression were used as biomarkers for differentiation. qPCR results show gene 
expression compared with GAPDH relative to the untreated monolayer cells. Both genes 
show an increase in expression when grown in the raft culture. E: Slot blot results for Vu40T 
cells grown in 3D. 1000ng DNA was blotted onto a nitrocellulose membrane and incubated 
with a 5mC or 5hmC antibody. 100nM DAC caused a minimal decrease in 5mC levels and a 
corresponding increase in 5hmC. F: Gene expression changes in Vu40T cells grown in 
organotypic raft culture in response to DAC treatment. G: RARβ expression in Vu40T cells 
grown in 3D raft culture, 2D monolayer in normal cell culture media or 2D monolayer in 
Emedia. RARβ expression was at minimally detectable levels in Vu40T cells when grown in 
the 3D culture system and decreased further following DAC treatment. 
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Discussion  
 
Cancer is a multifactorial disease with both genetic and epigenetic modifications 
contributing to its progression. For this reason therapeutic strategies involving the 
use of drugs which target aberrant epigenetic mechanisms such as HDAC 
inhibitors or demethylating agents are a promising pathway to pursue. Azacytidine 
(AZA) and its analogue 5-Aza-2’-deoxycytidine (DAC) have proven effective in the 
treatment of haematological malignancies and recent work suggests that the 
benefits of DAC treatment may be transferable to solid tumours (Issa et al., 2004, 
Leone et al., 2003, Kantarjian et al., 2006; Tsai et al., 2012). Both drugs act as 
demethylating agents that inhibit DNMT1 through their incorporation into DNA or 
RNA (Ghoshal et al., 2005). Progress in their use as anticancer drugs has been 
hindered by the fact that high doses can cause extreme toxicity however evidence 
suggests that low doses may have a therapeutic benefit without exerting the 
harmful side effects (Stressmann and Lyko, 2008). This project aimed to expand 
upon current knowledge of DAC treatment by treating oral cancer cell lines with 
varying concentrations of the drug either alone or in combination with retinoic acid.  
 
The efficacy of any cancer therapeutic pathway is tumour specific and dependent 
on the genetic and epigenetic makeup of the cells. In order to get a broader view 
on the effectiveness of DAC treatment on oral cancer two separate HPV-negative 
OSCC cell lines were studied; Vu40T and Scc040. The effect of DAC treatment 
varied considerably between the two cell lines. For each cell line four different 
concentrations of DAC were used either in combination with RA or independently.  
Initial observations on cell growth (Figure 3A-B) demonstrated that Vu40Ts were 
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more affected by the drug than the Scc040 cells. This was confirmed by pervious 
MTT assays undertaken by the laboratory (Wiench- Personal communications) 
which found that the IC50 for Vu40Ts in response to DAC treatment to be 
considerably lower (0.5-2.15μM) than that of Scc040 cells (>9μM).  In order to 
confirm the mechanism by which DAC exhorts its effect the global levels of 
methylation were determined via slot blot analysis. Results confirmed that DAC 
treatment reduced the global levels of DNA methylation in both cell lines (Figure 
4A-B, 5A-B). Therefore although Scc040 cells appear more resistant to the 
cytotoxic effects of DAC the ability of the drug to demethylate DNA in this cell line 
was equal to that in Vu40T cells. A potential explanation for the difference in the 
efficacy of the drug is that Scc040 cells start with less aberrant methylation than 
Vu40T cells and the progression of the cancer was determined by other 
mechanisms such as genetic mutations or irregular chromatin states.  
Furthermore it would be interesting to determine whether there is any difference in 
DNMT1 gene expression between the two cell lines as this can confer resistance 
to DAC treatment.  
 
RARβ is a tumour suppressor gene frequently silenced in solid tumours by 
epigenetic mechanisms (Connolly et al., 2013). In wild type cells its activation 
depends on retinoic acid binding to RARα which then induces the expression of 
RARβ as well as other target genes. Once active RARβ can mediate its own 
expression and activate its target genes. The main function of RARβ target genes 
is the control of cell differentiation and death (Connolly et al., 2013).   Therefore 
when RARβ cannot be activated the cells evade death which is a hallmark of 
cancer (Hanahan and Weinberg, 2000). The expression of RARβ after treatment 
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with DAC was determined to provide a quantitative measure of the efficacy of the 
drug as we know that RARβ is methylated in many cancer cell types and hence its 
reactivation is an indication of the level of demethylation occurring. The addition of 
RA to the treatment model provides the cells with excess retinoic acid to activate 
the retinoic acid receptors. The qPCR results presented showed different patterns 
of RARβ gene activation for each cell line (Figure 4C-5C). Vu40T cells are highly 
susceptible to DAC treatment and the change in RARβ expression is in 
agreement with this observation. As the concentration of DAC increased so does 
the level of RARβ and this was heightened by the addition of RA (Figure 4C). 
Scc040 cells were less susceptible to treatment and demonstrate minimal change 
in RARβ expression when treated with DAC alone (Figure 5C). However the 
addition of RA caused a considerable increase in RARβ expression (Figure 5C). 
These results suggest that RARβ is methylated in Vu40T cells but not Scc040 
cells and could partially explain why Scc040s are less susceptible to DAC 
treatment. This theory is supported when the levels of RARβ mRNA in Vu40T and 
Scc040 cells are compared (Figure 5D). The restriction digest results also showed 
higher levels of DNA methylation at the RARβ promoter in Vu40T cells than 
Scc040s however both cell lines demonstrated a decrease in methylation after 
DAC treatment (Figure 4D, 5E). Additionally both the Vu40T and Scc040 
restriction digest gels allow for comparison of the 182bp uncut band but do not 
show clearly any of the digested fragments making determination of the 
methylation status less distinct. Therefore it would be beneficial to repeat the 
experiment, including investigation into other sites in the RARβ gene, using other 
restriction enzymes or using another site-specific method for determining 
methylation levels such as methylation sensitive PCR.  
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The addition of RA causes an increase in RARβ expression in both cell lines 
which is in agreement with the pathway to RARβ activation outlined above. RAR 
activation relies on ligand binding so pharmacological doses of RA mean more RA 
available to the cell (Connolly et al., 2013). Therefore RA has been considered as 
a potential therapeutic pathway to directly target the loss of RAR tumour 
suppression and in some cases is effective (Lotan et al, 1995).  From these 
results I cannot state for certain that treating tumours which exhibit Scc040 cells 
characteristics with RA alone would provide an effective therapeutic strategy 
because the increase in RARβ expression seen may be in excess of what is 
required of a healthy cell. Repeating this experiment with a primary cell line from 
healthy oral epithelial cells may determine whether this is the case. However I can 
speculate that treating cancers with similar properties to Vu40T cells with DAC 
would have some therapeutic benefit via the reactivation of RARβ. 
 
A further finding of this study was that 5hmC levels were increased with DAC 
treatment (Figure 6A). DAC demethylates DNA via incorporation into DNA in place 
of cytosine where it immobilizes and degrades DNMT1 (Stressmann and Lyko, 
2008). This process was supported by the 5mC slot blot data which showed a 
dose dependent decrease in methylation in response to DAC treatment (Figure 
4A-5A). 5mC is converted into 5hmC by the TET proteins; therefore the presence 
of 5hmC is 5mC dependent (Tahiliani et al., 2009). It could be hypothesised that 
when treated with DAC cells would show a reduction in 5hmC. However this was 
not the case and alternatively 5hmC increased with DAC treatment in both cell 
lines (Figure 6A). Although slot blots provide an overview of the methylation or 
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hydroxymethylation status of the DNA the technique is not very sensitive as the 
slots in the manifold can become blocked. As each sample was run twice and 
each experiment repeated this resulted in four slots per sample to obtain a mean 
from to provide a more accurate estimation of the levels of 5hmC or 5mC in each 
sample (Figures 4B, 5B, 6A). 5hmC has been reported to be low in oral cancer 
cells (Jäwert et al., 2013) and a similar result was observed here as both Vu40T 
and Scc040 untreated cells exhibited little to no 5hmC. This explains why the 
bands remain faint for all samples however it is clear that at 500nM and 1µM DAC 
more 5hmC is present for both cell types (Figure 6A). Unpublished 
immunofluorescence data (Wiench- personal communications) showed decreased 
5hmC after DAC treatment for both cell lines confirming these findings. 
 
In order to explain this unexpected observation qPCR was performed on cDNA 
from all the samples using primers specific for the TET1 and TET2 transcripts. As 
the TET hydroxylases are required for the conversion of 5mC into 5hmC 
increases in either gene might explain the data presented (Tahiliani et al., 2009). 
Results demonstrated that TET1 appeared to decrease by ~50% for Vu40T cells 
with a concentration of DAC above 100nM with or without RA, conversely Scc040 
cells exhibited consistent levels of TET1 throughout the treatment (Figure 6B-C). 
Notably TET2 expression was at least doubled in both cell lines after treatment 
with DAC (Figure 6D-E). For Vu40T cells the effect of DAC on TET2 expression 
was only apparent after exposure to 500nM DAC when there was a 2.5 fold 
change from untreated cells, the same observation was seen when combined 
exposure with RA was applied (Figure 6D). Indeed treatment of Vu40T cells with 
RA alone also gave a slight increase in TET2 expression which corresponded with 
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the increased 5hmC levels seen in the slot blot analysis (Figures 6A-E). 
Interestingly Scc040 cells showed a more dramatic change in expression, after 
100nM DAC exposure the TET2 RNA levels doubled and expression was 7 times 
that of the control at 1µM DAC (Figure 6E). The addition of RA increased all of 
these results with 500nM DAC + 1µM RA showing 10 times the amount of TET2 
RNA as the control cells. These results identify a potential mechanism to explain 
how DAC treatment results in increased 5hmC levels. Although DAC leads to a 
decrease in the amount of 5mC via inhibition of DNMT1 it also causes an increase 
in TET2 expression which leads to more conversion of 5mC to 5hmC thereby 
increasing the levels of 5hmC (Figure 8). TET2 has already been shown to be 
decreased in oral cancers (Jäwert et al., 2013) so DAC treatment could provide a 
mechanism to bring about its reactivation and keep the levels of 5hmC high.   
 
 
 
5hmC is thought to be a step in the demethylation pathway however whether the 
modification has other functions remains unclear with some research suggesting 
that it may have functions beyond demethylation as distinct proteins bind to it and 
the other modified forms of cytosine (Iurlaro et al., 2013). Levels of 5hmC are 
reduced in various cancers; this may just be a biproduct of the increased 5mC 
commonly associated with cancer progression however it may suggest that the 
modification has tumour suppressive properties (Jäwert et al., 2013, Yang et al., 
Figure 8: Schematic Representing 
a Potential Mechanism by which 
DAC Treatment Could Increase 
5hmC Levels. In the presence of 
DAC expression of TET2 is 
increased leading to an increase in 
the conversion of 5mC to 5hmC. 
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2013).  Likewise Yang et al. (2013) showed that the TET proteins are decreased 
in several tumours types and Jäwert et al. (2013) specifically showed a decrease 
in TET2 in oral cancer. Our results are in keeping with these findings and suggest 
that TET2 and 5hmC may function as tumour suppressors.  
 
While the results presented here are preliminary, there are a number of further 
experiments which could be undertaken to confirm and expand upon our findings. 
Firstly the slot blot results would need to be confirmed with the use of another 
antibody. Additionally determining whether knock down of TET2 expression with 
si-RNA or an α-KG antagonist effects 5hmC levels after DAC treatment may help 
to confirm that TET2 reactivation causes the increase in 5hmC observed. Treating 
the cells with retinoic acid either alone or in combination with DAC caused an 
increase in the levels of 5hmC and TET2 in both cell lines (Figures 6A, 6D-E). 
Furthering these studies represents another area of future work. Firstly by 
determining whether any of the retinoic acid receptors are involved in regulation of 
TET2 gene expression, either by looking for the presence of RAREs in the TET2 
promoter or performing chromatin immunoprecipitation with each RAR to see if 
the proteins are associated with the TET2 promoter. As the RARs have been 
associated with tumour suppression these results provide further support to the 
theory that 5hmC and TET2 are involved in tumour suppression (Connolly et al., 
2013). 
 
The results presented here have also shown that sensitivity to DAC is dependent 
on the cell line used. Furthermore the cell culture method used can contribute to 
the variation in the results as is seen from Figure 7. When grown using the 3D raft 
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culture technique Vu40T cells not only expressed considerably less RARβ but this 
expression decreased upon DAC treatment (Figure 7G) unlike the monolayer 
culture data which showed a consistent increase in RARβ expression after DAC 
exposure (Figure 4C). The 3D culture results are representative of a single 
experiment unlike the monolayer results and as such further organotypic culture 
experiments are warranted. However previous research has also shown 
differences in gene expression in monolayers versus 3D culture with the latter 
being closer to that of in vivo tumours (Ridky et al., 2010). This suggests that in 
order to determine the accuracy and relevance of monolayer results the 
experiment should be repeated using a 3D platform.  
 
Conclusion  
 
This project aimed to determine the effect of low dose 5-Aza-2’-deoxycytidine 
either in combination with 9-cis retinoic acid or alone on oral cancer cells lines. 
We showed that response to the treatment model was cell line dependent which 
mirrored the variability of cancer cells in vivo. Vu40T cells responded well to DAC 
treatment showing a gradual dose dependent increase in the expression of the 
tumour suppressor gene RARβ. Scc040 cells however were much less sensitive, 
showing an increase in RARβ expression only upon addition of RA to the 
treatment. This data may suggest that RARβ is epigenetically silenced in Vu40T 
cells but not in Scc040 cells. Furthermore DAC treatment lead to an increase in 
the global levels of 5hmC via increased TET2 gene expression. These results 
provide two mechanisms by which DAC exerts its effects in the treatment of oral 
cancer and suggest it may represent a promising therapeutic pathway to pursue.  
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Abstract 
 
Hypoxia inducible factor (HIF) is the master regulator of the hypoxia 
response. The active form is composed of two subunits (α and β), in the 
presence of oxygen the alpha subunit is constantly degraded. HIF-α stability 
is controlled by the HIF prolyl hydroxylase domain proteins (PHDs) in an 
oxygen dependent process. Phd1 knockout mice show a shift in metabolism 
to produce more ATP through glycolysis and consume less oxygen. The aim 
of this project was to determine the respiratory phenotype of Phd1-/- mouse 
liver mitochondria. The results showed that loss of PHD1 altered the activity 
of mitochondrial complexes I-IV in a highly variable manner. Therefore the 
pathway from Phd1 knockout to decline in mitochondrial complex function 
is not a linear one. PHD1 can be induced by oestrogen and this project 
suggests that the effect of PHD1 loss on mitochondrial decline may be sex 
specific.  
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 Introduction 
 
The Role of Mitochondria in ATP Production 
Mitochondria produce 90% of cellular ATP. This is dependent upon an 
electrochemical gradient across the inner mitochondrial membrane created by 
respiratory complexes I-IV. The redox potential of the initial electron donor NADH 
is -340mV whereas O2, the final acceptor, has a redox potential of +810mV 
(Mailloux et al., 2013).Therefore the transfer of electrons from NADH to O2 is an 
energetically favourable process. This drives the transfer of protons across the 
inner membrane and creates the proton motif force (PMF) providing the energy 
required to fuel ATP production (Mailloux et al., 2013). 
 
Complex 1 (NADH dehydrogenase) spans the inner membrane. It shuttles two 
electrons from NADH to ubiquinone (Q) generating NAD and ubiquinol (QH2) 
(Davis and Williams, 2012). Succinate dehydrogenase or complex II transfers 
electrons from succinate to the Q pool via flavin adenine dinucleotide (FAD) 
(Davis and Williams, 2012). Electrons from QH2 are then transferred to 
cytochrome C by complex III (ubiquinol-cytochrome c (CytC) reductase). Finally 
Complex IV (cytochrome C oxidase) transfers electrons from cytochrome C to the 
final electron acceptor oxygen to create water (Mailloux et al., 2013; Davis and 
Williams, 2012). Complexes I, III and IV span the inner mitochondrial membrane 
and the transfer of electrons from NADH to O2 releases the energy required for 
them to pump protons (H+) across the membrane into the intermembane space 
(Wei et al., 2009). This proton gradient is harnessed by complex V, the F1F0 ATP 
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synthase to convert ADP to ATP (Mailloux et al., 2013). This is summarised in 
Figure1.  
 
 
ROS Production in the Mitochondria 
Mitochondria are also major producers of reactive oxygen species (ROS) 
(Shigenaga et al., 1994). The organelles are present in relatively high numbers, 
consume the most cellular oxygen and are rich in redox carriers (Shigenaga et al., 
1994; Andreyev et al., 2005). Therefore the organelles link to ROS production is 
inevitable.  Complex I and complex III are the best characterized producers of 
 
Figure 1: The Electron Transport Chain (ETC): Figure from Wei et al. (2009). The ETC spans 
the inner mitochondrial membrane and uses a series of redox reaction to fuel the transfer of 
protons accross the membrane. Complex I or NADH dehydrogenase converts NADH to NAD
+
 
and passes the electron to ubiquinone. Complex II (Succinate dehydrogenase) transfers 
electrons from succinate to the Q pool to generate fumerate. Complex III(ubiquinol-cytochrome c 
reductase) then transfers electrons from Q to cytochrome c (Cyt c). These are then taken by 
complex IV(cytochrome c oxidase) to generate H2O from O2. This process is energetically 
favourable so complexes I, III and IV use the energy released to pump protons across the 
membrane creating the proton motif force (PMF). The PMF is a store of energy which can be 
harness by complex V (ATP synthase) to generate ATP from ADP + Pi. Subunits of the 
mitochondrial complexes are encoded by a mix of nuclear (n) DNA and mitochondrial (mt) DNA.  
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ROS in the mitochondria although various other proteins also contribute 
(Andreyev et al., 2005). In the ETC electrons from complexes I and III (and 
occasionally II) can be released prematurely generating superoxide (O2
-) 
(Andreyev et al., 2005). This is converted into hydrogen peroxide (H2O2), the main 
species of ROS (Mailloux et al., 2013). H2O2 has a long half-life, can diffuse 
through membranes and is involved in various processes such as insulin 
signalling and response to hypoxia (Mailloux et al., 2013). However accumulation 
of H2O2 and O2
- can lead to the damage of DNA, RNA and proteins in various 
ways: they can lead to the production of the hydroxyl radical (OH) that 
indiscriminately oxidizes macromolecules; H2O2 can inactivate proteins by 
oxidizing redox-sensitive thiol groups; when combined with nitric oxide, O2
- forms 
the very toxic peroxynitrite species; or alone O2
- can disassemble iron-sulphur 
clusters causing damage to TCA cycle enzymes and respiratory complexes 
(Mailloux et al., 2013). As the main site of ROS production, mitochondria are 
particularly prone to damage by ROS.  A number of respiratory enzymes are 
encoded by DNA in the mitochondria (mtDNA) (Figure 1). Mutations are more 
frequent in mtDNA than nuclear DNA due to lack of protection by histones; less 
effective DNA repair systems and proximity to the site of ROS production (Wei et 
al., 2008). Therefore mitochondrial damage by ROS is two-fold; the proteins can 
be damaged directly or ROS can cause mutations in mtDNA leading to irreversible 
damage which is heritable across cellular generations (Wei et al., 2008).  
 
High mitochondrial membrane potential is linked to increased production of ROS 
and so one mechanism to limit accumulation of ROS is through uncoupling 
proteins (UCP1-3) (Korshunov et al., 1997; Mailloux and Harper, 2011). UCPs 
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transport ions across the inner mitochondrial membrane reducing the 
electrochemical gradient produced by the electron transport chain (Donadelli et 
al., 2013). UCPs are thought to leak protons across the membrane in order to 
prevent ROS emission, a theory confirmed by the excess ROS production seen in 
Ucp2 -/- mice (Mailloux and Harper, 2011).  
 
Mitochondria and Aging 
Since the 1950’s theories have linked ROS accumulation and subsequent 
mitochondrial damage with the natural process of aging (Harman, 1956; Wei et 
al., 2008). In young, healthy cells ROS are a natural biproduct of respiration but 
antioxidants and free radical scavenger enzymes prevent their accumulation (Wei 
et al., 2008). However as cells age the production of superoxide anions and H2O2 
increases and the capacity of antioxidants and free radical scavengers to remove 
them decreases (Wei et al., 2008). This leads to the accumulation of free radicals, 
subsequent damage to mitochondria, a shift in respiration efficiency and an 
increase in ROS production creating a vicious cycle of mitochondrial decline (Wei 
et al., 2008). Aged cells demonstrate an accumulation of mtDNA mutations, 
mitochondrial structural damage and a reduction in respiratory enzyme activity 
(Bandy and Davidson, 1990; Wei et al., 2008). Senescent fibroblasts from human 
skin and lung demonstrate decreased pyruvate dehydrogenase activity (PDC) and 
increased pyruvate dehydrogenase kinase (PDK) after treatment with H2O2 (Wei 
et al., 2008). PDC is required for the conversion of pyruvate to acetyl CoA and 
hence this reduction in activity will decrease entry of glycolytic intermediates into 
the TCA cycle and increase glycolytic production of ATP (Wei et al., 2008).  
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The Role of PHDs in the Control of HIF-α Stability 
In order to protect against hypoxia cells must induce the expression of numerous 
genes to reprogram metabolism and increase angiogenesis and erythropoiesis 
(Fong et al., 2008). This change in gene expression is controlled in the most part 
by hypoxia-inducible factor (HIF). The transcription factor is composed of two 
subunits α and β, under hypoxia these heterodimerize and bind to hypoxia 
response elements (HREs) where they induce the expression of their target genes 
(Applehoff et al., 2004). In normoxia the alpha subunit (HIF-1α, HIF-2α, HIF-3α) is 
constitutively expressed but constantly degraded by the proteasome (Applehoff et 
al., 2004; Bruik and McKnight, 2001). This degradation is controlled by a family of 
HIF prolyl hydroxylase domain proteins (PHD1, PHD2 and PHD3, also called 
ElgNs or HPHs) (Bruik and McKnight, 2001). The PHDs are Fe2+ and 2-
oxoglutarate-dependent dioxygenases and are highly sensitive to changes in 
cellular oxygen concentration (Kaelin and Ratcliffe, 2008). They hydroxylate 
prolines 564 and 402 on HIF-α creating a binding site for the von Hippel Lindau 
protein (VHL) which polyubiquitinates HIF-α targeting it for proteasomal 
degradation (Figure 2) (Papandreou et al., 2006). 
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PHD1 
The three PHDs all have the ability to hydroxylate HIF-α and induce HRE gene 
expression in vivo however they differ slightly in terms of function, activation and 
cellular location (Appelhoff et al., 2004; Metzan et al., 2003). Takeda et al. (2006) 
looked at the effect of knocking out each of the PHDs in mouse embryonic 
development and found that Phd1 and 3 knockouts were viable but Phd2-/- mice 
were embryonic lethal. PHD2 is the most abundant and thought to be the main 
regulator of HIF-1α (Appelhoff et al., 2004).  However the focus of this report is on 
PHD1. Unlike the other PHDs PHD1 is found exclusively in the nucleus and 
exhorts its effects mainly on HIF-2α in normoxia (Metzen et al., 2003; Appelhoff et 
al., 2004).   
 
Figure 2: The role of the PHD proteins in HIF-α control. In the presence of oxygen PHD 
proteins (1,2 or 3) use oxygen to hydroxylate HIF-α (1,2, or 3). This hydroxylation allows the von 
Hippel Lindau (VHL) protein to bind and polyubiquitinate HIF-α targeting it for degradation by the 
proteasome. In hypoxia PHDs cannot hydroxylate HIF-α so VHL cannot bind. HIF-α is therefore 
not degraded and can heterodimerize with HIF-β and induce the expression of genes 
downstream of hypoxia response elements (HREs). These bring about a change in metabolism, 
increased angiogenesis and erythropoiesis and reduced consumption of oxygen.  
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The gene was found independently by Seth et al. (2002) (referred to as EIT-6) in a 
screen for oestrogen dependent genes in a breast cancer cell line and shown to 
be a direct transcriptional target of the oestrogen receptor. In breast cancer cell 
lines, overexpression of Phd1 causes resistance to tamoxifen and leads to 
oestrogen independent growth linking PHD1 to oestrogen regulation and breast 
cancer progression (Seth et al., 2002). Appelhoff et al. (2004) confirmed this link 
as they found a 2.5 fold increase in protein levels after stimulation with oestrogen. 
Zhang et al., (2009) used siRNA to knock down PHD1 activity in various cell lines 
and found that this decreased cyclin D1 mRNA and protein levels and suppressed 
mammary gland proliferation. Inhibition of PHD2 or 3 had no effect (Zhang et al., 
2009). Furthermore this function of PHD1 appears to be HIF-independent as 
knock down of PHD1 had no effect on levels of either HIF-α protein and knocking 
down or overexpressing HIF-2α had no effect on the levels of cyclin DI in PHD1 
deficient cells (Zhang et al., 2009). The hydroxylase function of PHD1 however is 
still required to control the levels of cyclin D1 and therefore this process is oxygen 
dependent (Zhang et al., 2009). Similarly PHD1 has been seen to be involved in 
regulation of transcription factor NF-kB and centrosomal protein Cep192 in HIF-
independent processes (Cummins et al., 2006; Moser et al., 2013). These results 
show that PHD1 has functions beyond the control of HIF-2α.  
 
Phd1 knockout mice show reduced oxygen consumption and a shift in basal 
metabolism similar to that seen under conditions of hypoxia and in aged cells 
(Aragonés et al., 2008; Wei et al., 2008). Pyruvate dehydrogenase kinases 
(PDKs) inhibit PDC which is required for progression into the TCA cycle 
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(Aragonés et al., 2008). Aragonés et al. (2008) found that loss of PHD1 in skeletal 
muscle resulted in an increase in pdk1 and 4 at the mRNA and protein levels; this 
corresponded with a 54% reduction of PDC activity. The overall result of this is an 
increase in glycolytic production of ATP as glycolytic intermediates are prevented 
from entry into the TCA cycle (Aragonés et al., 2008). Schneider et al. (2010) 
made a similar discovery in the livers of Phd1-/- mice. Both papers linked this shift 
in metabolism to protection against acute ischemia, a phenotype specific to   
Phd1-/- as knock out of the other PHD genes did not have the same effect 
(Aragonés et al., 2008; Schneider et al., 2010). An increase in the levels of 
transcription factor Pparα was also observed (Aragonés et al., 2008). As this is 
known to regulate pdk4 it provides a potential step in the pathway from Phd1 
knockout to increased glycolysis. These papers propose that HIF-2α mediates this 
response as Phd1-/- mice show increased HIF-2α protein levels and when crossed 
with Hif-2α +/- mice the ischemia protection is lost (Aragonés et al., 2008).  
 
Aims and Objectives 
This project aims to determine the respiratory phenotype of mitochondria from 
Phd1 knockout mouse livers. The main objectives are to: 
-Isolate mitochondria from wild type and Phd1-/- mouse livers; 
-Determine the activity of respiratory complexes I-IV in these mitochondria; 
-Compare the effect of the age and sex of the mice used on these results.  
 
  
54 
 
Materials and Methods 
 
DNA Extraction from Mouse Ear Clips 
To each ear clip 200μl TNES buffer (5ml=500μl 100mM Tris, 800μl 2.5M sodium 
chloride (NaCl), 1ml 0.5M ethylenediaminetetraacetic acid (EDTA), 300μl 10% 
sodium dodecyl sulphate (SDS), dH2O) + 15μl Proteinase K (1mg/100μl) was 
added. These were incubated at 65oC for 3 hours. 56μl of 5M NaCl was added to 
each sample, vortexed and then centrifuged at 4oC at 14000g for 20 minutes. The 
supernatant was transferred to a new tube and two volumes of 100% ethanol 
added to precipitate the DNA. This was then centrifuge at 14000g for 10 minutes, 
the supernatant discarded and pellet washed in 70% ethanol. Once dried the DNA 
pellet was resuspended overnight at 37oC in 10mM Tris.  
 
Genotyping 
The mouse model used is described elsewhere and summarised in figure 3 
(Aragonés et al., 2008). To genotype the samples two PCRs were performed. One 
was using primers against exon 4 of the Phd1 gene (present in heterozygous and 
wild type animals) and one using primers against the inserted neomycin cassette 
(present in heterozygote and knockout animals). The PCR mix remained constant 
(2μl 20mM primers, 10μl MyTaq Buffer, 0.625μl MyTaq polymerase, 50ng DNA, 
dH2O) .The programme varied depending on the primer pair. For neomycin: 95
oC 
for 1 minute, then 30 cycles of 95oC for 15 seconds, 65oC for 15 seconds and 
then 72oC for 10 seconds, followed by 1 minute at 72oC. For exon 4 the PCR 
programme was the same with the exception that the annealing temperature was 
changed to 60oC.  
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Products were run on a 1.5% (neomycin) or 2% (exon 4) agarose gel in 1X TAE 
for 20 minutes at 100V. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isolation of Liver Mitochondria 
Mitochondria were isolated from wild type and Phd1-/- livers of varying ages by 
differential centrifugation as described in Frezza et al.’s paper (2007) with a few 
deviations from the protocol. In brief the isolated livers were minced and 
immersed in isolation buffer at a ratio of 1:5-1:10 (w:v). This was then 
homogenized by 4-8 strokes of a Teflon pestle and transferred to a centrifuge 
tube. The homogenate was centrifuged for 10 minutes at 500g, supernatant 
transferred to a new tube and centrifuged for 10 minutes at 1000g; the 
 
Figure 3: Generation of Phd1
-/-
 mice. Figure taken from Aragonés et al., 2008. A: Wild 
type (wt) Phd1 allele. B: schematic of the targeting vector used to generate Phd1 
knockouts. A neomycin cassette (Neo) flanked by regions homologous to the wild type 
gene was used to knockout the central two exons of Phd1. A thymidine kinase (TK) gene 
outside of the homologous section was used to allow selection against random insertion 
events. C: After homologous recombination of the wild type allele and the targeting vector a 
Phd1
-
 allele was generated. Note, the numbering of the exons in this figure does not 
correlate with the real allele; one exon is missing from the image. So the neo cassette in 
the targeting vector replaces exons 3 and 4 instead of 2 and 3. 
A. 
B. 
C.
.. 
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supernatant was spun at 13000g for a further 10 minutes. This resulted in a pellet 
of mitochondria which was washed in isolation buffer and centrifuged at 7000g for 
a further 10 minutes.  The above was carried out at 4oC or on ice.  
 
Suspension in Detergent Buffers 
The resulting mitochondria were quantified using the Pierce BCA kit (Thermo 
Scientific: PI-23221).  The mitochondria were centrifuged for 10 minutes at 
10,000g; remaining isolation buffer removed and the pellet resuspended in 
digitonin or dodecylmaltoside (DDM) buffer.   
 
Ratios of DDM: mitochondria (g:g) or digitonin: mitochondria (g:g) varied 
(digitonin: mitochondria= 4:1 or 3:1; DDM: mitochondria= 0.5:1 or 1:1). The buffers 
were prepared using the NativePAGE sample Prep Kit (Invitrogen: BN2008) and 
1μl protease inhibitor (Sigma: P8340) per 100μl buffer. The buffers were allowed 
to interact with the mitochondria for 20 minutes then they were centrifuged at 
55000g for 15 minutes. 
 
Blue Native Gel Electrophoresis (BNE) 
NativePAGE sample additive (Invitrogen: BN2008) was added to 100μg of 
mitochondria and loaded onto a 4-16% Bis-Tris Polyacrylamide gel (Novex: 
BN2111BX10) alongside 7μl NativeMark unstained protein standard (Life 
Technologies; LC0725).  NativePAGE running buffer (Novex: BN2001) was used 
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with 0.02% Coomassie Blue(NativePAGE Cathode Buffer Additive Invitrogen: 
BN2002) added to the cathode buffer until the sample moved a third down the gel 
then this was replaced with a cathode buffer consisting of 0.002% Coomassie. 1X 
NativePAGE running buffer was used as the anode buffer. Gels were run at 4oC at 
100V until the sample entered the gel then it was turned up to 300V. Gels were 
washed in dH2O and stained with SimplyBlue (Invitrogen: LC6060).  
 
Mass Spectrometry 
Bands corresponding to known molecular weights of respiratory complexes I-V 
were cut from a BNE gel and sent for mass spectrometry to determine all proteins 
present in each band. The MitoMiner programme (Smith et al., 2012) was used to 
analyse the results.  
 
High Resolution Clear Native Electrophoresis (hrCNE) 
Clear Native electrophoresis was used to separate the above samples as of a 
previously described protocol (Wittig et al., 2007). Briefly 100μg of mitochondria or 
7μl NativeMark protein standard was loaded into a NativePAGE 4-16% Bis-Tris 
Polyacrylamide gel (Novex: BN2111BX10). Digitonin samples were separated 
using a cathode buffer consisting of 1XNativePAGE running buffer (Novex: 
BN2001) with 0.05% sodium deoxycholate (DOC) and 0.01% DDM whereas DDM 
samples had 0.02% DDM in this mix. The anode buffer remained constant as 1X 
NativePAGE buffer. The gels were run at 100V until the sample entered the gel 
then it was turned up to 300V. hrCNE was performed in 4oC for 3.5 hours. 
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In Gel Catalytic Activity Assays 
After hrCNE the lanes were cut out the gel and in gel catalytic activity assays for 
mitochondrial complexes I-IV performed. This has been previously described 
(Wittig et al., 2007) with complex I and II assays performed on the same gel strip. 
Complex I buffer: 2.5mg/ml NitroBlue Tetrazolium (NTB)(Fisher Bioreagents: 
BP108-1); 0.1mg/ml β-nicotinamide adenine dinucleotide reduced dipotassium 
salt (NADH) (Sigma N4505), in 5mM Tris/HCl. Complex II buffer: 2.5mg/ml NTB, 
200μl IM sodium succinate, 8μl 250mM phenezine methosulfate in 5mM Tris/HCl. 
Complex III buffer: 0.5mg/ml DAB in 50mM sodium phosphate. Complex IV buffer: 
0.5mg/ml DAB and 1mg/ml cytochrome c powder in 50mM sodium phosphate. 
Gels were fixed in a solution of 10% acetic acid, 50% methanol and then washed 
in dH2O. The protein standard and neighbouring samples were incubated in 
SimplyBlue stain (Invitrogen: LC6060) for 1 hour then washed in dH2O.  
 
The ImageJ programme (Schneider et al., 2012) was used to determine the 
intensities of each band form the activity assays. These were then normalised to 
the intensity of the corresponding band on the blue native gel and shown relative 
to the wild type control. 
 
Western Blot 
For each sample 20μg was boiled at 100oC for 10 minutes in Laemmli sample 
buffer (Sigma: S3401-IVL). These were then loaded onto a 12% Tris-SDS 
acrylamide gel alongside 5μl Amersham Full-range rainbow molecular weight 
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marker (GE Healthcare: RPN800E). The gel was run at 150V in Tris/Glycine/SDS 
running buffer (Geneflow: B9-0032). Transfer to the nitrocellulose membrane was 
carried out using the wet transfer method for 1 hour at 100V. The gel was 
incubated in Quick blue Coomassie stain (triple red) overnight at room temp to 
stain for all remaining proteins on the gel and the nitrocellulose membranes 
blocked for an hour in 5% non-fat milk in PBST and incubated with the primary 
antibody UCP2 (Santa Cruz: Sc6526) at 1:500 dilution overnight at 4oC. The 
primary antibody was washed off and the secondary antibody (Donkey Anti-goat 
Santa Cruz: Sc-2020 at 1:2000) allowed to bind for 1 hour at room temperature. 
This was then washed and visualised using the Amersham ECL detection kit (GE 
Healthcare: RPN2232).  
ImageJ was used to determine the intensities of each UCP2 band. This was 
normalised to the intensity of the whole of the corresponding lane on the 
Coomassie stained gel and shown relative to the wild type band.  
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Results 
Genotyping 
The construct used to generate Phd1-/- mice has been described previously 
(Aragonés et al., 2008). It entails using a neomycin cassette to replace two exons 
of the wild type gene. Therefore in order to genotype the offspring PCR was 
performed using two sets of primers; one pair flanking the neomycin cassette and 
one pair against one of the missing exons. Figure 4A shows an example of how 
the genotyping was done; the homozygous knockout mice used in this project had 
been genotyped prior to the start.  In the example litter shown, the parental cross 
was between a Phd1+/+ mouse and a Phd1+/- so no Phd1-/- are present in the litter. 
Pups 1-10 and 13 are all wild type as they only produce bands when primers 
flanking exon 4 are used. Pups 11, 12 and 14 however are heterozygous as they 
produce bands for both primer pairs.  
 
DDM versus Digitonin 
Wild type mouse livers were used to refine the experimental procedure. The 
mitochondrial extraction procedure is based on a series of centrifugation steps 
that allows for the isolation of a fraction rich in mitochondria (Frezza et al., 2007). 
This was resuspended in detergent buffer to solubilise the mitochondria prior to 
native gel electrophoresis. Two buffers are commonly used in this procedure; 
digitonin and dodecylmaltoside (DDM) (Wittig et al., 2007). In this project both 
buffers were used. Digitonin is one of the mildest known detergents so 
supramolecular associations of multiprotein complexes were not disrupted (Wittig 
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et al., 2007) (Figure 4B). After clear native gel electrophoresis in gel catalytic 
assays were performed for respiratory complexes I-IV, this provides a semi-
quantitative means of determining the ability of each complex to function. When 
solubilised in digitonin buffer complexes I, II and IV were isolated individually but 
additional bands were seen on the complex I gel: these represent 
supercomplexes where complex I is found in association with complex III and/or 
IV (Schagger and Pfeiffer, 2000). DDM is a mild non-ionic detergent which was 
able to isolate complexes I-IV individually (Figure 4C). When mitochondria were 
solubilised in DDM the activity of complex III can be determined (Figure 4C). This 
was not the case for digitonin buffer (Figure 4B). However DDM cannot maintain 
some of the protein-protein interactions between the individual respiratory 
complexes that link them together as supercomplexes. Therefore in order to get 
the most accurate view on the organisation and activity of the respiratory 
complexes both DDM and digitonin detergents were used to solubilise the isolated 
mitochondria. 
 
Using wild type mouse liver mitochondria, different ratios of each buffer was used 
to try to determine which yields the clearest results. For digitionin buffer the ratios 
of detergent: mitochondria (g:g) used were 2:1, 3:1 and 4:1. Both 3:1 and 4:1 
ratios provided clear results on the activity of each complex examined (Figure 4B). 
However the 4:1 ratio shows an additional faint band in the complex IV gel 
confirming its presence in the supercomplexes (Figure 4B). Therefore a ratio of 
4:1 digitonin: mitochondria was used in this project. DDM: mitochondria ratios 
examined were 0.5:1 and 1:1 (Figure 4C). The results did not vary greatly 
between the two concentrations so a ratio of 1:1 DDM: mitochondria was used.  
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Blue Native Gel Electrophoresis (BNE) 
Mitochondria solubilised in DDM or digitonin buffer were separated using blue 
native gel electrophoresis (BNE). This technique uses Coomassie dye in the 
cathode buffer and added directly to the samples to impose a charge shift in all 
proteins in the sample so that they all migrate to the anode. The BNE gels 
highlight two things; firstly it clearly shows that digitonin buffer was the only one 
able to isolate the supercomplexes as more bands were apparent in this 
detergent; secondly it shows that there is little to no difference in the size of each 
complex between the pairs of mice (Figure 4D). Each BNE shows the results of 
mitochondrial isolated from four separate pairs of age and sex matched mice; one 
Phd1-/- and one wild type sib. In both buffers the bands on the BNE were matched 
for each pair suggesting that any differences in activity found in the activity gels 
was not due to differences in the protein levels between matched samples (Figure 
4D).  
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Figure 4: Refining the Experimental Procedure. A: example of genotyping results. DNA 
was extracted from offspring of a Phd1
-/+ 
X Phd1
+/+
 cross. Two PCRs were performed, one for 
the native exon 4 and the other for the knocked in neomycin cassette. Pups 11, 12 and 14 are 
Phd1
+/-
 (Het), the rest are Phd1
+/+
(wt). PCR products were electrophoresised on a 1.5% (neo) 
or 2% (exon 4) agarose gel. B-D:  After isolation mitochondria were solubilised in DDM or 
digitonin buffer. These were then separated on a 4-16% Bis-Tris gel at 300V for 3.5hours. B: 
Mitochondria were resuspended in digitonin buffer at ratios of 2:1, 3:1, 4:1 digitonin: 
mitochondria (g/g). Clear native gel electrophesis was performed using a cathode buffer 
containing 0.01%DDM and 0.05%DOC. In gel catalytic activity assays were performed on 
resulting gel strips. Complex I and II assays were performed sequentially on the same gel 
strip. In order the bands in the CI+CII gel represent: supercomplexes I+II; complex I; then 
complex II. C: Isolated mitochondria were solubilised in DDM buffer at a ratio of 0.5:1 or 1:1 
DDM: mitochondria (g/g). hrCNE was performed using a cathode buffer containing 0.02% 
DDM and 0.05% DOC. D: Mitochondria from wild type and Phd1
-/-
 mice were solubilised in 4:1 
digitonin (left) or 1:1 DDM (right) buffers. 100μg was loaded onto a gel and run using a 
cathode buffer containing 0.02% Coomassie dye that was replaced with 0.002% Coomassie 
after the sample had moved through a third of the gel. Resulting gels were washed in 
SimplyBlue stain for 1hr then in dH2O overnight. w/o: weeks old. SI: supercomplex I, CI: 
complex I, CII: complex II, CIII: complex III, CIV: complex IV, CV: complex V. 7μl NativeMark 
Protein Standard (life technologies) wass loaded alongside the samples in all gels.  
 
A. 
B. C. 
D. 
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Phd1 Knockout Causes a Reduction in The Activity of Respiratory Complex 
I, II and IV. 
 
Mitochondria were isolated from the livers of a 27 week old female Phd1-/- mouse 
and an age and sex matched wild type sib. These were then solubilised in 4:1 
digitonin buffer and run on a clear native gel. In gel catalytic activity assays were 
performed for complexes I-IV on the resulting gel strips. Incubation in complex III 
buffer provided no results, as was seen in the wild type digitonin practice gels. 
Complex I and IV buffers however presented clear differences in the activity of 
each complex in Phd1-/- mitochondria (Figure 5A).  The activity of complex IV was 
almost completely abolished in the knockout mice. The complex I results show a 
similarly striking reduction in activity. Complex II isn’t so visibly affected by loss of 
Phd1 (Figure 5A).  
 
In order to quantify the data ImageJ was used to determine the intensities of each 
band. The results are shown here in two different forms. For every sample 100μg 
of protein was loaded into the well. Therefore the results are first shown as the 
intensity of the Phd1-/- activity relative to the wild type control (Figure 5B).  In 
addition to this the results are normalised to the corresponding band from the BNE 
to account for errors in calculating protein concentration (Figure 5C). These 
results are shown as a fold change from the wild type sib. Both gels show the 
same pattern of activity, although the reduction in complex II activity is only visible 
when the results were normalised to the BNE. The activity of complex I is down by 
75% in Phd1-/-, complex II is reduced by almost 20% and complex IV by over 95% 
(Figure 5C).  
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DDM Buffer Alters the Activity of Respiratory Complexes I and IV from Phd1 
Knockout Mouse Mitochondria. 
Mitochondria from the same 27 week old female mice were solubilised in DDM 
buffer.  These were separated by clear native gel electrophoresis and in gel 
catalytic activity assays for mitochondrial complexes I-IV performed. Interestingly 
when solubilised in DDM buffer Phd1-/- mitochondria did not show the same 
reduction in complex I, II and IV activity as was found in the digitonin buffer 
(Figure 5A-5C). Instead the activity of each complex was either unaffected or 
increased in Phd1-/- mitochondria with the intensity of the band representing 
complex II being considerably stronger in the Phd1-/- mitochondria (Figures 5D-F). 
This may be due to an error in the experimental procedure or may be a direct 
effect of the detergents. 
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Figure 5: Loss of PHD1 Causes a Reduction in the Activity of Respiratory Complexes I, II 
and IV in 27 Week Old Female Mice. A: Mitochondria from a Phd1
-/-
 27 week old female 
mouse and an age/sex matched wild type sib were solubilised in 4:1 digitonin: mitochondria 
buffer. 100μg was loaded onto a 4-16% Bis-Tris acrylamide gel and electrophoresis was 
performed using 0.01% DDM and 0.05% DOC cathode buffer. In gel activity assays were 
preformed for complex I, II and IV. The NativeMark protein standard and neighbouring lanes 
were incubated in SimplyBlue stain. A single gel strip shows complex I and complex II activity. In 
order the bands show, supercomplex I +II, complex I and then complex II at the bottom. B-C: 
ImageJ data from gels in A. B: Intensity of the bands is shown relative to the wild type control. 
C: Results from B are normalised against the corresponding band on the BNE gel (Figure 4D). 
D: Mitochondria from the same 27 week old female mice were solubilised in 1:1 DDM buffer. 
hrCNE was performed using 0.02%DDM in the cathode buffer. Gel strips were incubated in 
complex I-IV buffers. Complex III buffer yeilded no results. Complex I+II assays were preformed 
on the same strip sequentially. E-F: ImageJ was used to calculate the intensity of bands from D. 
E: The density of each band is shown relative to the wild type control. F: Results from E are 
normalised to the corresponding band from the BNE gel (Figure 4D).  
 
A. B. 
C. 
D. 
E. 
F. 
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Phd1 Knockout May Reduce Respiratory Complex Activity More in Aged 
Mice. 
It is well documented that deterioration of mitochondria is linked to the aging 
process (Wei et al., 2008). As mentioned previously the mice used so far in this 
project were 27 weeks old so the severity of the phenotype observed may be due 
to the age of the mice.  Therefore mitochondria from a 10 week old female Phd1-/- 
mouse and an age and sex matched wild type sib were isolated. These were 
solubilised in digitonin buffer, separated on a clear native gel and complex I, II and 
IV activity assays performed on the resulting gel strips. In this pair of mice the 
activity of complex I was unaffected by loss of PHD1 (Figure 6A). As before the 
activity of complex IV was reduced in the mutant, however in the 10 week old 
mice the reduction in activity was less than 25% of the wild type whereas the 27 
week old mice saw a reduction in activity of over 95% (Figure 6A-C). The activity 
of complex II in the knockout mouse mitochondria was only 27% of that of the wild 
type control (Figure 6C). This is much less than the activity of complex II in 
mitochondria from the 27 week old Phd1-/- mouse (Figure 4C).  These results 
suggest that the age of the mice does affect the severity of mitochondrial decline 
in Phd1-/- mice.   
 
Again when solubilised in DDM buffer the results differed to those found in 
digitonin buffer. Complex I and IV showed a greater decrease in activity in DDM 
buffer than they did in digitonin buffer whereas the decrease in complex II activity 
was less (Figure 6A-C). Complex III activity is only visible when mitochondria are 
solubilised in DDM buffer and these results showed that loss of PHD1 causes a 
decrease in activity of over 80% in 10 week old mice (Figure 6D-F). 
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Figure 6: Age May Alter the Respiratory Phenotype of Phd1 Knockout Mitochondria. A, D: 
Mitochondria were isolated from a 10 week old female Phd1
-/- 
mouse and an age and sex 
matched wild type sib. These were solubilised in digitonin buffer at a ratio of 4:1 digitonin: 
mitochondria (A) or DDM buffer at a ratio of 1:1 (D). 100µg of each sample was loaded onto a 4-
16% Bis-Tris gel and hrCNE performed using 0.01% (A) or 0.02% (B) DDM and 0.05% DOC in 
the cathode buffer.  Enzyme activity assays specific for complexes I-IV were preformed on the 
resulting gel strips. NativeMark protein standard and neighbouring strips were incubated in 
SimplyBlue stain for 1hour. B-C: The intensity of each of the bands from A were calculated using 
ImageJ. B: Density is shown relative to wild type sib. C: Data from B was normalised to the 
density of the corresponding band in the BNE (Figure 4D). E-F: relative intensities of bands from 
D. E: ImageJ was used to determine density of each band relative to the corresponding wild type 
sib. F: Data from E was normalised to the corresponding band of the BNE (fig). 
A. 
B. 
C. 
D. E. 
F. 
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Phd1 Knockout May Have Sex Specific Effects. 
PHD1 is a target of the oestrogen receptor so the protein may have sex specific 
roles and the effect of Phd1 knockout may differ between the sexes (Seth et al., 
2002). The previous mice examined were female therefore mitochondria from a 40 
week old Phd1-/- male mouse and an age and sex matched wild type sib were 
isolated. These were solubilised in digitonin buffer, separated by CNE and 
complex I, II and IV activity assays performed. Unlike previous results the activity 
of all complexes appeared to increase by 20% or more in the mutant mice (Figure 
7A-C). Similarly when solubilised in DDM buffer the activity of complexes I- IV was 
either unaffected by the loss of PHD1 or increased with it (Figure 7D-F). These 
results suggest that the decline in respiratory complex activity observed in Phd1-/- 
mice is specific to females.  
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Figure 7: Knockout of Phd1 May Have Sex Specific Effects. A, D: Mitochondria from a 40 
week old male Phd1
-/-
 mouse and an age and sex matched wild type sib were solubilised in 4:1 
digitonin buffer (A) or 1:1 DDM buffer (D). 100μg mitochondria was loaded onto a 4-16% Bis-
Tris gel and hrCNE performed using a cathode buffer containing 0.01% (A) or 0.02% (D) DDM 
and 0.05% DOC. Activity assays for complexes I-IV were preformed on the resulting gel strips. 
NativeMark Protein Standard and neighbouring lanes were incubated in SimplyBlue stain for 
1hour. B-C: Relative density of bands from A. B: ImageJ was used to determine the intensity of 
each band from A, Phd1
-/-
 bands are shown relative to the wild type control. C: results from B 
are normalised to the corresponding band in the BNE (Figure 4D). E-F: Relative density of 
activity assays from D. E: Density of bands from D are shown relative to the wild type sib. F: 
Results from E are normalised to the density of the corresponding bands in the BNE (Figure 
4D). 
A. B. 
C. 
F. 
E. 
D. 
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Loss of PHD1 has a Variable Effect on the Activity of Complexes I-IV. 
Mitochondria were isolated from two more Phd1-/- female mice of about 30 weeks 
old and two wild type sibs. These mice resembled the initial pair in both age and 
sex. However the results of the in gel activity assays do not match (Figure 8A, E). 
In one pair loss of PHD1 increased complex I activity, specifically when found in 
the supercomplex (Figure 8A). The activity of complex II was unaffected and 
complex IV activity decreased by less than 10% when solubilised in digitonin 
buffer (Figure 8A). Only the activity of complex III is shown in DDM buffer as this 
cannot be seen when the mitochondria are solubilised in digitonin. Complex III 
activity was reduced by almost 75% in the Phd1-/- mouse (Figure 8A-D).  In the 
other pair complex IV activity was reduced by 67% in the Phd1-/- mitochondria but 
the activity of all the other complexes was increased with complex III activity being 
over two fold higher in the mutant (Figure 8E-H). These results show that there is 
huge variability in the effects of PHD1 loss on mitochondrial complex activity. The 
results for all 30 week female mice were combined and show that the general 
trend of PHD1 loss is a reduction in the activity of complex I by about 15% and 
complex IV by almost 60% (Figures 8I-J). In this figure, complex II appears 
unaffected and complex III activity increased in the mutant. However the complex 
III result is due to a single pair of 30 week old mice which showed a huge increase 
in activity in the mutant (Figure 8F-H).  
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Figure 8: The Effect of PHD1 Knockout on Respiratory Complexes Activity Varies. A, B, E, 
F: Mitochondria were isolated from two 30 week old female Phd1
-/-
 mice and two age and sex 
matched wild type sibs. A-B and E-F represent two independent experiments. Mitochondria were 
solubilised in 4:1 digitonin (A, E) or 1:1 DDM (B, F) and 100μg of each sample was loaded onto a 
4-16% Bis-Tris gel. hrCNE was performed using a cathode buffer containing 0.01% (A, E) or 
0.02% (B,F) DDM and 0.05% DOC. Enzyme activity assays were performed on resulting gel 
strips. NativeMark protein standard and neighbouring lanes were incubated in SimplyBlue stain 
for 1 hour. C-D: ImageJ was used to determine the relative density of bands from A and B. 
Complex I, II and IV data are from digitonin buffer (A), complex III data is from DDM buffer (B). C: 
Density is shown relative to wild type sib. D: Results from C are shown normalised to the 
corresponding BNE band (Figure 4D). G-H: Relative density of bands from E and F. G: ImageJ 
was used to determine the density of each band relative to the control. H: Results from G were 
normalised to the corresponding band on the BNE gel (Figure 4D). I-J: Average results for all 
three pairs 30 weeks old females. I: ImageJ was used to determine the density of bands for each 
activity assay. Phd1
-/-
 results are shown relative to the wild type sib. J: Relative density of the 
bands from I was normalised to the corresponding band form the BNE gel (Figure 4D). 
A. B. 
D. 
C. 
F. 
G. 
H. 
I. J. 
E. 
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Mitochondria from Phd1 Knockout Mouse Livers have Less UCP2.  
The variability of the results lead to the hypothesis that respiratory complex 
decline is not a direct result of PHD1 loss. A potential explanation for this could be 
that Phd1-/- mitochondria produce more reactive oxygen species than wild type. 
These would indiscriminately damage proteins and DNA in the mitochondria. 
Therefore a UCP2 western was performed on the isolated mitochondria. UCP2 
spans the inner mitochondrial membrane, controls the electrochemical potential of 
the membrane and as such can control the amount of ROS produced (Donadelli 
et al., 2013). In lieu of a stable mitochondria specific control gene the total protein 
content on the gel was determined by staining the gel with Coomassie and density 
of the UCP2 band was normalised to this (Figure 9B). The overall pattern was a 
reduction in UCP2 levels in the Phd1-/- mitochondria (Figure 9B). However 
mitochondria from the male mouse had increased UCP2 levels in the Phd1 
knockout and the reduction in UCP2 in the majority of the females was only 
between 5 and 10% (Figure 9B).   A single 30 week female showed 75% less 
UCP2 in the Phd1-/- mitochondria than the wild type however this result did not 
correlate with that of the activity assays (Figure 8A).  
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Figure 9:  UCP2 protein levels were reduced in Phd1
-/-
 female mice. A: 20μg of 
mitochondria solubilised in digitonin buffer was loaded onto an SDS gel and a western blott for 
UCP2 performed (top). After blotting  the remaining proteins in the gel were stained using 
Coomassie blue (bottom). B: ImageJ data shows insensity of UCP2 band normalised to that of 
the blue gel. Phd1
-/- 
data is shown relative to the corresponding wild type sib. Results are 
combined from two independent experiments. w/o= weeks old. 
A. 
B. 
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Mass Spectrometry Confirms Reduced Function of Complex I in 27 Week 
Old Phd1-/- Mitochondria.  
Blue native gel electrophoresis was performed using 100μg of mitochondria 
isolated from the 27 week old female mice discussed previously. Bands 
corresponding to respiratory complexes I-V were excised from the gel using 
published molecular weights as a guideline (Wittig et al., 2006). Mass 
spectrometry was performed to determine all proteins present in each band. 
Analysis of the bands from complexes II, III and IV suggests that the wrong bands 
were excised as the presence of the relevant subunits in each band was minimal. 
However complex I bands were rich in NADH dehydrogenase subunits and 
complex V bands rich in ATP synthase subunits suggesting that these bands were 
correct. The MRC MitoMiner programme was used to analyse the results (Smith 
et al., 2012).  All bands were enriched for mitochondrial proteins, however 
proteins from peroxisomes and the endoplasmic reticulum were also present 
showing that although differential centrifugation produces a fraction rich in 
mitochondria it does not completely eliminate contamination by other organelles.  
 
The MitoMiner programme was used to determine which UniProt keywords were 
enriched in each sample (Smith et al., 2012). Along with showing which organelles 
are present this gives an indication of the biological processes carried out by the 
proteins in the sample. The top 12 results are shown in Table 1.  Irrelevant 
keywords such as those from organelles other than mitochondria were removed. 
The table shows the p-values for enrichment of the Phd1-/- and wild type samples 
against the default background population calculated by the MitoMiner programme 
using hypergeometric distribution. For complex I p-values for oxidoreductase and 
76 
 
NAD are lower in the mutant than the wild type. This indicates that there are fewer 
proteins involved in the transferral of electrons to/from NAD(H) in the Phd1-/-  
sample. As the function of complex I is to transfer electrons from NADH to 
ubiquinone this is consistent with the 75% reduction in complex I activity seen in 
the activity assays (Figure 5C). Interestingly the complex V results show that the 
p-value for ATP synthesis in the Phd1-/- sample is lower than that of the wild type 
suggesting that ATP production in the knockout is higher than normal (Table 1B).  
 
Consistent across both complex I and complex V samples is the fact that proteins 
involved in fatty acid and lipid metabolism are less enriched in Phd1-/- than wild 
type samples (Tables 1A-B). This is interesting as the livers of Phd1-/- appeared to 
be less fatty than their wild type counterparts. Additionally there is an increase in 
H+ ion transport in the Phd1-/- samples (Tables 1A-B).  Previous results have 
shown reduced activity of complexes I and IV and reduced levels of UCP2 in 
these mitochondria both of which would suggest less H+ transport. The mass 
spectrometry results therefore might suggest that the complex I subunits damaged 
in the Phd1-/- mitochondria are those involved in the reduction of NADH not the 
transport of H+ ions across the inner mitochondrial membrane.  
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Table 1: Differential Enrichment in WT and Phd1
-/- 
Mass Spectrometry Samples. Mitochondria 
from 27 week Phd1
-/- 
female mouse and age and sex matched wild type sib were solubilised in 
DDM buffer, separated by BNE and the bands corresponding to each complex in the respiratory 
chain excised and sent for mass spectrometry. The MitoMiner programme was used to look for 
UniProt keywords enriched in the resulting data. Tables show the top 12 results for complex I (left) 
and V (right). Keywords unrelated to mitochondria were removed from the data. The numbers 
shown are the p-values calculated by MitoMiner using hypergeometric distribution to determine 
which UniProt keywords were enriched in the proteins present in the wild type and Phd1
-/-
 samples.  
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Discussion 
 
In normoxia the PHD proteins control the degradation of HIF-α by hydroxylating 
specific residues which allows for the VHL protein to bind and ubiquitinate 
(Papandreou et al., 2006; Bruik and McKnight, 2001). This process is oxygen 
dependent. In the absence of oxygen PHDs cannot hydroxylate HIF so VHL 
cannot bind and HIF-α can dimerize with HIF-β and control the hypoxia response. 
HIF-α is constitutively expressed so this mechanism provides a quick means of 
responding to drops in oxygen concentration (Applehoff et al., 2004). The active 
HIF dimer induces the expression of genes involved in erythropoiesis and 
angiogenesis and brings about a change in basal metabolism so that less oxygen 
is consumed (Papandreou et al., 2006). Evidence is starting to suggest that the 
PHD proteins may also have roles outside of HIF-α control (Appelhoff et al., 2004; 
Zhang et al., 2009; Cummins et al., 2006; Moser et al., 2013) .PHD1 has been 
linked to regulation of cyclin DI, NF-kB and Cep192 levels in processes 
completely independent of HIF (Zhang et al., 2009; Cummins et al., 2006; Moser 
et al., 2013).  
 
The vast majority of cellular ATP is produced in the mitochondria (Mailloux et al., 
2013). Glycolysis occurs in the cytosol and in normoxia most glycolytic 
intermediates are passed to the matrix of the mitochondria where the TCA cycle 
occurs. This produces the NADH required to fuel the electron transport chain 
(Mailloux et al., 2013). Complexes I-IV of the electron transport chain carry out a 
series of redox reactions transferring electrons from the initial electron donor; 
NADH to the final acceptor; oxygen (Wei et al., 2009; Mailloux et al., 2013) 
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Complexes I, III and IV all span the tightly controlled inner mitochondrial 
membrane and they use the energy produced from this transfer of electrons to 
transport hydrogen ions across the membrane to create a proton gradient (Wei et 
al., 2009). The gradient is a store of energy which is harnessed by complex V 
(ATP synthase) to produce ATP (Wei et al., 2009; Davis and Williams, 2012). This 
process requires oxygen so in hypoxia the HIF proteins regulate a shift in 
metabolism so that more ATP is produced by glycolysis and less oxygen is 
consumed by the mitochondria (Papandreou et al., 2006). PDK1 is induced by 
HIF-1 causing a reduction in PDC activity (Papandreou et al., 2006). PDC controls 
the conversion of pyruvate to acetyl CoA so this means reduced entry of glycolytic 
intermediates into the TCA cycle and increased glycolysis during hypoxia 
(Papandreou et al., 2006). Aragonés et al. (2008) found a similar process was 
occurring in the skeletal muscle of mice lacking PHD1. They proposed that this 
occurred through HIF-2α and protected the muscle against ischemia (Aragonés et 
al., 2008). A similar result was observed in Phd1-/- mouse livers (Schneider et al., 
2010). This project aimed to expand upon these findings and examine the 
respiratory phenotype of mitochondria from Phd1-/- mouse livers.  
 
Differential centrifugation was used to isolate mitochondria from the livers of  
Phd1-/- mice and an age and sex matched wild type sib. The resulting 
mitochondria were then solubilised in detergent buffer and separated by native gel 
electrophoresis. In gel catalytic activity assays specific to each of the four 
mitochondrial complexes were preformed to provide a semi-quantifiable means of 
determining differences in the ability of each complex to function in the mutant 
mice. The overall conclusion drawn from these experiments was that loss of Phd1 
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leads to a reduction in the activity of complexes I-IV. However this result varied 
greatly between the different pairs of mice used in terms of how much activity was 
lost in the mutant and which of the four complexes were affected (Figures 5-8). 
 
The affect of age and sex on these results were considered. Mitochondrial decline 
is thought to be closely linked to aging (Wei et al., 2008). As cells age the ability to 
prevent ROS accumulation declines and that this damages the mitochondria (Wei 
et al., 2008). Therefore mitochondrial damage resulting from PHD1 loss may 
accumulate with age. The results showed that the activity of the respiratory 
complexes was less in a 27 week old Phd1-/- mouse than a corresponding 10 
week old mouse (Figure 5-6). However this was not the case when a further two 
pairs of 30 week old mice were examined. Instead both Phd1-/- mice showed less 
mitochondrial damage than was seen in the 10 week old mouse (Figure 8A-H). 
Therefore we cannot conclude from these findings that the loss of complex activity 
in Phd1-/- mouse mitochondria increases with age. More young mice would need 
to be used in order to determine whether there is a correlation. As PHD1 is 
thought to be a direct target of the oestrogen receptor it may have sex specific 
functions (Seth et al., 2002). The 10-30 week old mice used in this project were all 
females. Therefore the activity of the respiratory complexes of mitochondria from 
a 40 week old male Phd1-/- mouse and an age and sex matched wild type sib were 
determined. Mitochondria from the male Phd1-/- mouse showed no loss of activity 
in complexes I-IV and instead a slight increase in activity was observed (Figure 
7A-F). This would suggest that the affects of Phd1 knockout on the respiratory 
phenotype of mouse liver mitochondria is sex specific. However in order to 
confirm this theory the experiment would need to be repeated with more males. 
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Additionally matching the age of the males with the females would provide more 
accurate results.  
 
This project has shown that loss of PHD1 causes extremely variable effects on the 
activity of mitochondrial complexes I-IV. This would suggest that the pathway from 
Phd1 knockout to mitochondrial damage is not a linear one. A promising 
hypothesis is that PHD1 loss causes an increase in the amount of reactive oxygen 
species produced within the cell. Mitochondria are prone to damage by ROS and 
as ROS are known to damage DNA and proteins indiscriminately the effects 
would vary with each mouse producing differences in the severity and location of 
the damage. This is in fitting with the variability of the results in this project. 
Therefore the levels of superoxide in Phd1-/- livers could be assessed for example 
by staining with the oxidative fluorescent dye dihydroethidine (Scortegagna et al., 
2003). Additionally treating the mice with antioxidants and seeing whether wild 
type mitochondrial phenotype is restored would provide evidence that loss of 
respiratory complex activity in Phd1-/- mice is due to excess ROS production. 
However as ROS may have also damaged mtDNA functional decline in the 
respiratory complexes may not be completely restored by antioxidant treatment. 
Interestingly another facet of hypoxia signalling involves the inhibition of PHD 
proteins by excess ROS (Guzy and Schumacker, 2006). It is thought that in the 
initial stages of hypoxia mitochondria produce more ROS which target the Fe2+ ion 
required by the PHD proteins (Guzy and Schumacker, 2006). Therefore if Phd1 
knockout leads to an increase in ROS this could in turn inhibit the function of the 
remaining PHDs.  
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ROS accumulation could be due to two things; either more ROS are being 
produced or the ability of antioxidants and ROS scavengers to control the levels of 
ROS are reduced. High mitochondrial membrane potential has been linked to 
increased ROS production (Korshunov et al., 1997). A Clarke-type electrode can 
be used to measure respiration in isolated mitochondria (Frezza et al., 2007). 
Coupled mitochondria should consume oxygen faster in the presence of ADP and 
this rate should increase when an uncoupler is added. This project aimed to use 
this technique to determine whether Phd1-/- mitochondria were more coupled than 
wild type and therefore have a higher membrane potential. However problems 
with the isolation procedure meant that the mitochondria isolated were not intact 
enough for this experiment. Therefore a UCP2 western was performed. UCP2 
spans the inner mitochondrial membrane and can uncouple the membrane by 
allowing ions across (Donadelli et al., 2013). The western showed a general 
reduction in UCP2 in the Phd1-/- mitochondria however this was not consistent 
across all pairs of mice examined. In keeping with the theory that loss of PHD1 
has sex specific affects the mitochondria from the 40 week old male mice showed 
an increase in UCP2 of over 75% (Figure 9A-B). The reduction in UCP2 levels 
seen in the females was generally only 5-10% with the results of a single 30 week 
old female being over 75% less UCP2 in the mutant (Figure 9A-B). However 
differences in these results do not correlate with those of the activity assays 
suggesting that loss of UCP2 is not the sole reason for mitochondrial damage in 
Phd1-/- mice.  
In addition to the regulation of HIF-2α stability PHD1 has HIF-independent roles 
(Zhang et al., 2009; Cummins et al., 2006). Scortegagna et al. (2003) found an 
increase in the activity of complex II and complex IV in skeletal myofibres from  
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Hif-2α knockout mice. These results are consistent with those discussed in this 
project as the opposite effect was observed; complex II and IV activity was 
reduced in Phd1-/- mitochondria. Schneider et al. (2010) showed an increase in 
HIF-2α protein levels in Phd1-/- mice using the mouse model discussed in this 
project. Additionally the protection against hypoxia observed in Phd1-/- mice is 
partially lost upon addition of HIF-2α siRNA, suggesting that this is HIF-2α 
dependent (Schneider et al., 2010). However whether this increase in HIF-2α is 
sufficient to cause the increase in glycolytic production of ATP and decrease in 
oxygen consumption observed in Phd1-/- mice is not discussed (Schneider et al., 
2010; Aragonés et al., 2008). Therefore the functional decline of respiratory 
complexes I-IV in Phd1-/- mice discussed in the current report may be due to the 
increased levels of HIF-2α previously seen in the mouse model used but more 
work needs to be done to determine whether this is the case (Schneider et al., 
2010). Repeating the experiments with Phd1-/- mice crossed with Hif-2α+/- mice 
would be the first step in doing so.  
Mass spectrometry was performed on bands corresponding to complexes I-V of 
the ETC from Phd1-/- mouse mitochondria. Unfortunately the results for complex II, 
III and IV suggested that the wrong bands were excised from the gel. Therefore 
this would need to be repeated, perhaps by using a protein stained strip from a 
hrCNE gel instead of that of a BNE gel. This way the complex activity assays 
could be performed alongside it and the relevant bands more easily determined. 
The complex I results showed a drop in enrichment in proteins involved in NAD 
and oxidoreductase which corresponds with the reduction in complex I activity 
shown in the in gel catalytic assays (Table1/Figure 5A). An increase in proteins 
involved hydrogen ion transport was observed in both the complex I and complex 
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V samples. This could provide a potential mechanism to explain the theory of 
excess ROS production in Phd1-/- mice as it may suggest a higher membrane 
potential at the inner mitochondrial membrane (Korchunovet al., 1997). However 
the transport of protons could go both ways and these results are that of a single 
mouse so more work is needed in order to prove this.  
 
Conclusion 
 
This project has shown that Phd1 knockout results in a decline in function of 
mitochondrial complexes I-IV. However this result varies considerably suggesting 
that a linear pathway from Phd1 loss to mitochondrial damage does not exist. A 
potential mechanism to explain this variability is through increased ROS 
production in the mutant which would damage mitochondrial proteins and DNA 
arbitrarily. More work needs to be done in order to prove this; first by repeating the 
experiment with more age and sex matched mice then determining whether  
Phd1-/- mice show increased levels of ROS. The results also suggest that the 
mitochondrial decline observed in Phd1-/- mice may be sex specific as the male 
mouse examined did not show the same pattern of mitochondrial complex activity 
loss found in the females. 
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